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Abstract
Ovarian cancer is the deadliest gynecological malignancy affecting women. Diagnosis
often occurs late due to non-specific symptoms, but if detected early, there is excellent
chance for survival. One of the most important risk factors is family history. Up to 24%
of cases are due to inherited loss-of-function mutations in genes involved in the DNA
damage response. The theory underlying hereditary cancers is Knudson’s two-hit theory
of cancer causation, where two hits are necessary for cancer to occur in an individual: one
in the germline and one in the tissue. The genes, CHEK1 and CHEK2, are modulators of
the DNA damage response, and could be susceptible to a first hit. There is little to no
evidence about whether loss-of-function mutations in either of these two genes can lead
to ovarian cancer. Using a cohort of 587 ovarian cancer cases and 557 controls, this study
sought to determine if CHEK1 and CHEK2 are associated with ovarian cancer. Applying
Fisher’s exact test to compare mutation rates and the t test to compare age at time of
diagnosis, the alternative hypothesis about an association between disease and mutations
in CHEK1 and CHEK2 was rejected, but an association between younger age at diagnosis
in cases and mutations in either gene was confirmed. The association between age and
mutations in either of these genes suggests that there is some influence of age on disease,
but a clear association between development of disease and mutations cannot yet be
established. This research has implications for social change: By recognizing the need to
test earlier in women with mutations in CHEK1 and/or CHEK2, they will have a higher
chance of survival and better health outcomes, not only for ovarian cancer but for related
cancers as well.
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Chapter 1: Introduction to the Study
Introduction
Inherited mutations are a strong causative component for ovarian cancer, one of
the deadliest cancers affecting women. Genes such as BRCA1 (BRreast CAncer), BRCA2,
and other genes involved in DNA repair have been associated with increasing ovarian
cancer risk (Pennington & Swisher, 2012). Two genes that are involved in the DNA
repair response are the genes CHEK1 and CHEK2. It is unclear whether these genes
could be associated with increased risk for ovarian cancer. This study aimed to
understand whether there is a possible association between mutations in these genes and
ovarian cancer susceptibility. If these two genes are identified as such, then they can be
included in the genetic testing panels to determine risk of disease in women with known
family history of ovarian carcinoma. If women know they are at risk, they can pursue
prophylactic strategies, as well as improved surveillance techniques, to either prevent
cancer or identify cancer early. Improving cancer survival rates is a positive social
change that in turn leads to prevention and improved surveillance.
The current chapter provides background for the current study, information on
why this study was pursued, and the questions this study sought to answer. It also gives
an introduction to the conceptual framework of the study and presents the limitations,
assumptions, scope and delimitations, and significance of the study.
Background of the Study
The term ovarian cancer refers to tumors in ovaries, fallopian tubes, and/or
peritoneum (Chen & Berek, 2015). It is the deadliest gynecological cancer that affects
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women; it represents 3% of cancers that occur in women; and ranks as the ninth most
common cancer overall (Surveillance, Epidemiology and End Results, 2012). Five-year
survival rates are low (46%) compared to breast cancer (89%) and cervical cancer (70%),
as reported by Weissman, Weiss, and Newlin (2012). Survival rate is highly dependent
on the stage of the cancer at diagnosis. Early diagnosis corresponds with better outcomes.
Yet only 15% of ovarian cancers are diagnosed early because the disease tends to present
with non specific and non gynecological symptoms at later stages of the disease (Goff,
Mandel, Muntz, & Melancon, 2000; Weissman et al., 2012).
One of the most important risk factors for ovarian cancer is family history
(Pennington & Swisher, 2012). Hereditary ovarian cancer is due to inherited mutations in
different genes and accounts for 25% of newly diagnosed cases (Pennington & Swisher,
2012). The most common causes of inherited ovarian cancers are loss-of-function
germline mutations in BRCA1 and BRCA2 (BReast CAncer), which account for 48% and
27% of cases, respectively. However, at least 25% of hereditary ovarian cancer cases are
due to mutations in other genes (Pennington & Swisher, 2012).
In the early 1990s, researchers identified the genes BRCA1 and BRCA2 as
genetic elements that are responsible for inherited breast and ovarian cancer (Check,
2006). This led breast cancer researchers to acknowledge that complex traits and diseases
can be linked to mutations in certain genes. Genetic mutations are not just confined to
diseases that are of Mendelian inheritance, such as cystic fibrosis or Huntington’s disease
(Check, 2006). Genetic testing for mutations in these two genes has been performed since
the mid-90s. Women found to have mutations in BRCA1 and BRCA2 have an increased
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lifetime risk of breast and ovarian cancer and may elect to undergo preventative measures
to avoid disease. Not only were women who had mutations in BRCA1 and BRCA2 found
to have an increased risk of disease (Check, 2006), but they were also more likely to
develop disease earlier than women without mutations in these genes (Malone et al.,
2006). This suggests that age of diagnosis could also be correlated with mutations in
these susceptibility genes.
Other genes found in a DNA repair pathway, named the Fanconi Anemia-BRCA
pathway (FA-BRCA), have been associated with hereditary ovarian cancer (Pennington
& Swisher, 2012). The FA-BRCA DNA repair pathway is involved in the repair of DNA
by homologous recombination (HR, Pennington & Swisher, 2012). PALB2, RAD51C,
and RAD51D are genes that function in the FA-BRCA DNA pathway along with BRCA1
and BRCA2. Mutations in the afore mentioned genes have been correlated with ovarian
cancer cases (Casadei et al., 2011; Loveday et al., 2011; Vaz et al., 2010). With the
advent of new, highly efficient techniques for sequencing, such as targeted capture and
massively parallel sequencing, gene mutations can be investigated for correlation with
ovarian cancer and other diseases. These techniques also may identify previously
unknown genes that could impact disease (Walsh et al., 2011).
Walsh et al. (2011) performed a study using a massively parallel sequencing
approach (called BROCA) to sequence 21 tumor-suppressor genes on DNA from ovarian
cancer patients (Walsh et al., 2011). They found mutations in 12 genes, including BRCA1
and BRCA2, and new candidate genes such as BARD1, BRIP1, and CHEK2, all of which
had been suspected of conferring risk for ovarian cancer (Pennington & Swisher, 2012).
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In addition, Walsh et al. (2011) found that the average age in mutation carriers was lower
than in non-carriers. Inherited mutations are present in a larger number of genes than
previously thought, so identifying candidate genes involved in inherited ovarian cancer is
important (Walsh et al., 2011). CHEK1 and CHEK2 are appropriate genes to investigate
given the known involvement of other FA pathway genes in ovarian cancer (Chen &
Sanchez, 2004; Cybulski et al., 2004; Shaag et al., 2005). They are both part of the FABRCA DNA repair pathway and important effectors of the DNA damage response.
Identifying new candidate genes and including these genes in genetic testing can improve
the outcomes for women with a family history of ovarian and breast cancer. There is
support in the literature for including these variables in this study, which is discussed
further in Chapter 2.
Problem Statement
Ovarian cancer is among the top five causes of cancer death in American women
(SEER, 2012). Survival rates for ovarian cancer patients are low since most women are
diagnosed with advanced stages of the disease (Pennington & Swisher, 2012). When
detected early, there is an excellent chance for cure, but current methods of early
detection are largely ineffective. One of the most important risk factors for the
development of ovarian cancer is family history. Inherited mutations in genes (such as
BRCA1, BRCA2, PALB2, BARD1, and RAD51C) involved in DNA repair by HR
(Pennington & Swisher, 2012) may contribute to the risk of a woman’s chance of
developing the disease. Genetic testing for mutations in these genes has been helpful in
identifying potential mutation carriers. Many women with a family history of the disease
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and with loss of function mutations, especially in BRCA1 and BRCA2, have undergone
prophylactic salpingo oophorectomies, which in turn have led to reduced incidence of
disease and mortality (Pennington & Swisher, 2012).
Yet there are many women with family history of ovarian cancer but no loss of
function mutations in the known genes. This suggests that there may be other genes that
can harbor inherited mutations and lead to susceptibility to ovarian cancer. Two genes
that have been largely overlooked to date are CHEK2 and CHEK1. Both genes encode for
serine/threonine kinases and are important regulators of the cell cycle and mediators of
the DNA damage response (Shaag et al., 2005). Mutations in CHEK2 have previously
been associated with breast cancer and other types of cancer, such as prostate, lung, and
thyroid (Cybulski et al., 2004). Mutations within these genes can lead to truncated
proteins and promote errors in DNA repair. Since both CHEK1 and CHEK2 are important
players in the DNA damage response and are putative tumor suppressor genes, it is
important to determine whether they are likely candidates for mutations in ovarian cancer
patients. To date, only one publication has reported a mutation in CHEK1 in an ovarian
cancer patient (Pennington et al., 2013a), but no other publication has identified CHEK1
as a candidate gene for ovarian cancer; the research on CHEK2 and ovarian cancer is not
extensive and has not established a clear association. The literature reviewed in Chapter 2
demonstrates that these are appropriate candidate genes to study.
Purpose of the Study
The purpose of this quantitative study was to use data obtained at the University
of Washington to compare the rates of mutations in the genes CHEK1 and CHEK2 in
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ovarian cancer cases and healthy controls. Mutations were ascertained by a nextgeneration sequencing approach. Once the mutations were identified in the cohort, I
determined whether mutations in these genes were correlated with younger age at time of
diagnosis in the cases. Determining these rates and comparing cases contributes to the
growing evidence in favor of including CHEK1 and CHEK2 as candidate genes for
ovarian cancer. The results of this study are expected to allow researchers to investigate
whether these genes are susceptible to mutations and whether they can be designated as
ovarian cancer susceptibility genes.
Research Questions
The following four research questions guided this study:
H1: Are CHEK2 mutated alleles associated with ovarian cancer?
H01: There are no CHEK2 mutated alleles associated with ovarian cancer.
Ha1: CHEK2 mutated alleles are associated with ovarian cancer.
H2: Are CHEK1 mutated alleles associated with ovarian cancer?
H02: There are no CHEK1 mutated alleles associated with ovarian cancer.
Ha2: CHEK1 mutated alleles are associated with ovarian cancer.
H3: Are CHEK1 mutated alleles associated with younger age (<60 years of age) at
diagnosis in ovarian cancer cases?
H03: There is no association between younger age at diagnosis and CHEK1
mutations in ovarian cancer cases.
Ha3: Mutated alleles in CHEK1 are associated with younger age (<60 years of
age) at diagnosis in ovarian cancer cases.
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H4: Are CHEK2 mutated alleles associated with younger age (<60 years of age) at
diagnosis in ovarian cancer cases?
H04: There is no association between younger age at diagnosis and CHEK2
mutations in ovarian cancer cases.
Ha4: Mutated alleles in CHEK2 are associated with younger age (<60 years of
age) at diagnosis in ovarian cancer cases.
Conceptual Framework
In 1971, during his work on retinoblastoma, Alfred G. Knudson proposed that
germline mutations can lead to cancer (Knudson, 1971). This theory is referred to as the
two mutation theory of cancer causation. Knudson also proposed that all cancers were
either hereditary or sporadic (Knudson, 1971; Ormiston, 1996). In the case of hereditary
cancers, a germline mutation occurs pre-fertilization and is replicated in all cells created
post-fertilization (Ormiston, 1996). Knudson also proposed that, for cancer to occur in
these individuals, there needs to be another mutation that occurs as an error within one of
the many mitotic divisions that occur over a lifetime (Ormiston, 1996). He also
postulated that hereditary cancers occur at a younger age and that there is a higher
likelihood of recurrence as well as the occurrence of tumors at multiple sites (Knudson,
2002; Ormiston, 1996). In comparison, sporadic tumors occur much later in life and,
usually, there is only a single tumor site with very low likelihood of recurrence
(Knudson, 2002; Ormiston, 1996).
Individuals with germline mutations in BRCA1 and BRCA2 are diagnosed with
cancer at a younger age and often have multiple tumor sites (breast, ovaries, fallopian
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tubes, peritoneum, pancreas, etc.) compared with women who are diagnosed with breast
cancer due to somatic mutations but not germline mutations (Check, 2006; Ormiston,
1996). Additionally, in accordance with Knudson’s hypothesis, many tumors from cancer
patients with inherited breast and ovarian cancer syndrome have been found to have
mutations in genes such as TP53, a tumor suppressor protein involved in a number of
cellular processes (Greenblatt, Chappuis, Bond, Hamel, & Foulkes, 2001). Based on this
evidence, Knudson’s two mutation theory of cancer causation is an appropriate
framework for this study.
Definition of Terms
Mutation or variant: Change in the DNA sequence of a gene, it can range from a
single base to a large segment of a chromosome (Mutation, 2013).
Wildtype allele: The natural state of the DNA as it occurs in the majority of the
population; the opposite of being mutant (Wildtype allele, 2013)
Susceptibility genes: genes that if they contain mutations can predispose to a
particular disease such as cancer (Genetic susceptibility, 2015)
Salpingo-oophorectomy: surgery to remove fallopian tubes and ovaries (Mayo
Clinic, 2015)
Debulking sugery: complete or near complete removal of the tumor by surgical
means (American Cancer Society, 2015a)
Germline mutation: a mutation that is present in every cell of the body, because it
originated in a germ cell (Germline mutation, 2015)
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Loss-of-function mutation: mutation that results in the loss of function of a protein
(Loss of function, 2015)
Sequencing: Process by which the order of the nucleotides in a given DNA
fragment is determined (Sequencing, 2013).
Sanger Sequencing: Method developed by Fred Sanger to determine the order of
specific bases in a DNA fragment (Obenrader, n.d.).
Massive parallel sequencing approach: Also known as next-generation
sequencing (NGS) is a high throughput approach to DNA sequencing where several
sequencing reactions are occurring in parallel (Tucker, Marra, & Friedman, 2009).
Proband: A subject that is enrolled in genetic testing and affected by a condition
that is being studied. Often the first person tested within a family (Proband, 2015).
Occult cancer: Cancers that are hidden, and not clinically apparent. Most often
they are found through serial sectioning of ovaries and fallopian tubes in women who
underwent risk reducing salpingo-oopherectomy (Brown & Palmer, 2009).
Limitations
This study used secondary data (collected by the Swisher laboratory at the
University of Washington in Seattle), which limited my ability of to control the data
gathering process (Sorensen, Sabroe, & Olsen, 1996). Therefore, I was not able to
validate the data to confirm that the mutations were reported accurately nor to confirm
whether there were errors in the reporting of cancer status or age.
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Assumptions
This research was based on five assumptions: (a) the controls were cancer free at
the time of blood sample collection; (b) all proper protocols for DNA extraction and
analysis were performed according to standards set forth by the Clinical Laboratory
Improvement Amendments (CLIA); (c) measures were taken to prevent contamination
and mishandling of samples (Centers for Medicaid and Medicare Services, 2014); (d)
age was reported accurately at time of sample collection; (e) CHEK1 and CHEK2
influence the mechanisms of ovarian cancer development in the same way due to their
similarity of function within the DNA repair pathway.
Scope and Delimitations
This work is part of a genetic association study in which two candidate genes
were evaluated regarding their association with ovarian cancer. This study was a casecontrol study with available sequence data to determine whether the genes CHEK1 and
CHEK2, which functioned as the variables, harbored mutations more often in cases than
in controls. Cases were defined as women undergoing primary surgery for ovarian cancer
at the University of Washington (UW) between 2001 and present. Controls were defined
as healthy women over the age of 50. The age of the controls was a limitation of the
dataset given to me. It was assumed that the women treated at the University of
Washington were residents of the Pacific Northwest and that they represented the
population of that area, a population that may differ in race and ethnicity from women
living in other areas of the country. Information on where the participants lived was not
available; thus, I could not ascertain whether they represent only one area of the country.
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Data to determine CHEK1 and CHEK2 mutation was generated by next-generation
sequencing and provided in form of an Excel database. Statistical association analysis
was performed by chi-square (tests or Fisher’s exact tests, as appropriate, to
determine probability of disease association with mutations (Casadei et al., 2011).
This study was delimited to determining the type of mutation within each sample
that showed a mutation in CHEK1 and CHEK2. It did not (a) determine the mutation
rates in other genes (b) establish how mutations in CHEK1 and CHEK2 may or may not
contribute to ovarian cancer nor whether mutations in these genes were causative. The
data were correlated only to the study population .
Significance of the Study
The role of genes in addition to BRCA1 and BRCA2 in inherited ovarian cancer
have been investigated and confirmed, especially for genes involved in DNA repair
pathways (Pennington & Swisher, 2012; Walsh et al., 2011). Identifying genes in the
DNA repair pathway that may be susceptible to mutations associated with ovarian cancer
may help improve prevention and could lead to the development of new therapeutic
agents. Women at risk for hereditary ovarian cancer who carry mutations in certain genes
may choose a proactive approach to surveillance and treatment (Weissman et al., 2012).
Genetic counseling and testing may also include these genes to help improve disease
prevention, reduce incidence, and increase survival rates.
The improved medical knowledge from this research includes identification of
CHEK1 and CHEK2 as candidates for association with ovarian cancer and their inclusion
on genetic testing panels for hereditary ovarian cancer. It brings about social change
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because testing for these genes in addition to BRCA1 and BRCA2 and other genes may
result in reduced ovarian cancer incidence and increased survival rates. It may also be
cost-effective, because prophylactic efforts, such as surveillance and prophylactic
surgery, incur less cost than current medical treatments and tumor removal and debulking
surgery (Grann, Panageas, Whang, Antman, & Neugut, 1998). Additionally, genetic
testing can be expanded to include various family members and improve outcomes within
that family unit.
Summary
One of the most important risk factors for ovarian cancer is family history and
several genes can acquire mutations that increase an individual’s lifetime risk of disease
(Check, 2006; Pennington & Swisher, 2012). Many of these genes have been found to be
important players in the DNA damage response pathway (D’Andrea, 2013). CHEK1 and
CHEK2 are important mediators for the DNA damage response pathway and, if mutated,
could contribute to the development of ovarian cancer (Cybulski et al., 2004; Huang et
al., 2008; Kumar et al., 2013). Little is known about their involvement in ovarian cancer
risk. Novel sequencing techniques allow researchers to identify mutations in several
genes in tandem at lower costs and much more quickly, too (Walsh et al., 2011). These
techniques can provide sequencing information to determine whether CHEK1 and
CHEK2 can harbor mutations and become ovarian cancer susceptibility genes. This study
is a case control study that sought to determine whether there is an association between
mutations in those genes and disease and whether disease occurs earlier if mutations are
present.
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Chapter 2 reviews the literature on ovarian cancer genetics, current knowledge of
hereditary cancer syndromes, and how mutations in certain genes can lead to an increase
in cancer risk. Chapter 2 also discusses why CHEK1 and CHEK2 are suitable as potential
candidates for association with ovarian cancer. Chapter 3 presents the research methods
and research questions. Chapter 4 provides the results of this study and Chapter 5
discusses them. It also offers recommendations for future study.
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Chapter 2: Literature Review
Introduction
Ovarian cancer is the deadliest of all gynecological cancers and among the top
five causes of cancer-related death among American women (Surveillance, Epidemiology
and End Results, 2013). The strongest risk factor for development of disease is family
history correlated with the presence of mutations in different genes of the HR DNA repair
pathway, such as BRCA1 and BRCA2 (Pennington & Swisher, 2012). The purpose of this
study was to determine whether two genes involved in the HR repair pathway, CHEK1
and CHEK2, are associated with the development of ovarian cancer and whether they are
suitable candidates for ovarian cancer susceptibility.
In this chapter, the literature on the role of genetics in ovarian cancer, and the
known ovarian cancer susceptibility genes within the DNA repair pathway was
reviewed.It provides a basic introduction to the function of CHEK1 and CHEK2, the
known mutations in these genes, which are linked to different cancers, and the likelihood
that they could be candidate genes for ovarian cancer susceptibility.
To identify peer-reviewed articles, the following databases—PubMed, CINAHL,
Web of Science, SCOPUS, and Embase—were searched, without regard to year, using
these keywords: ovarian cancer, ovarian cancer genetics, hereditary breast and ovarian
cancer syndrome, hereditary cancer syndromes, BRCA1, BRCA2, Fanconi Anemia-BRCA
pathway, massively parallel sequencing, Next-Generation sequencing, BROCA, two hit
theory of cancer causation, Knudson’s two hit theory, CHEK1, and CHEK2. The Boolean
operators, AND and OR, were applied to optimize the results. . No limits other than
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language—English, Spanish or German—were set on the searches. Abstracts were used
to judge an article’s relevancy to the research questions.
Hereditary Ovarian Cancer
Ovarian cancer is the deadliest of all gynecological cancers and is among the top
five causes of cancer-related death in American women, with an estimated 14,030 deaths
in 2013 (National Cancer Institute, 2013). It is the ninth most common occurring cancer
with an estimated 22,240 new cases in 2013 in the U.S. (NCI, 2013). The survival rates
for ovarian cancer patients are low since most women present with symptoms at
advanced stages of the disease (Hunn & Rodriguez, 2012). The overall survival rate for
all types of ovarian cancer is 44%. When women are diagnosed at stage one of the
disease, their survival rate is 98%. However, those diagnosed at stage four have a
survival rate of only 18% (American Cancer Society, 2014). Only 15% of ovarian
cancers are identified early but when detected early, women have better recovery odds.
Attempts to improve early detection have been ineffective (Hunn & Rodriguez, 2012).
Most patients present symptoms late in the disease’s lifecycle and therefore identification
of molecular biomarkers that appear early in cancer development has been a challenge
(Hunn & Rodriguez, 2012). In addition, changes in tissue organization are hard to
determine due to the lack of accessibility to the ovaries (Hunn & Rodriguez, 2012). This
makes ovarian cancer risk very difficult to identify. Identification is, therefore, highly
dependent on epidemiological factors.
One of the most important risk factors for ovarian cancer is family history.
According to Jervis et al. (2015) the risk for first degree relatives of ovarian cancer
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patients is three fold higher than that of women without any known breast or ovarian
cancer in their families. Initial evidence for a familial link for ovarian cancer was
provided by case control studies performed in the late 1980s and 1990s. In a case control
study performed by Koch et al. (1989), there was a higher number of first and second
degree relatives with ovarian cancer in the families of cases compared to families of
controls.
Schildkraut et al. (1989) also investigated the genetic relationship between breast,
ovarian, and endometrial cancer and found that there was a strong genetic component to
these cancers. These researchers were part of the Cancer and Steroid Hormone Study
(CASH) led by the Centers for Disease Control and Prevention (CDC). The study
included information from multiple centers, and the investigators found elevated relative
risks for mothers and sisters of ovarian cancer cases (RR = 2.8) as well as for breast
cancer cases (RR = 1.6) (Schildkraut, Risch, & Thompson, 1989). They also found an
elevated risk for ovarian and breast cancer among other relatives of cases with these
cancers (RR = 2.1) (Schildkraut et al., 1989). They applied a multivariate polygenic
threshold model to establish that there was a strong genetic component of ovarian cancer.
Estimated hereditability of ovarian cancer was approximately 40% and 56% for breast
cancer (Schildkraut et al., 1989). With these results, the researchers established the first
link between ovarian cancer as a possible hereditary syndrome.
Using the same data from the CASH study, Claus et al. (1993) determined that
there was an increased lifetime risk (13–31%) for a woman to develop breast cancer
when a first or second degree relative had ovarian cancer, suggesting a genetic link not
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only for ovarian cancer itself but also with breast cancer. The likelihood of developing
one of these cancers within a family with a member suffering from either breast or
ovarian cancer is quite high (Claus, Risch, & Thompson, 1993). These studies therefore
support the notion that ovarian cancer is part of a number of cancers that can be dubbed
“hereditary cancer syndromes,” where mutations in specific genes are passed on from one
family member to another and can lead to cancer.
Hereditary Cancer Syndromes
Approximately 5-10% of all cancers are due to hereditary cancer syndromes,
where individuals in the family may pass on mutations in specific genes (Banks, Moline,
Marvin, Newlin, & Vogel, 2013). One important example for inherited cancer syndrome
is hereditary breast and ovarian cancer due to mutations in the BRCA1 and BRCA2 genes
(Banks et al., 2013; Garber & Offit, 2005). Men and women with inherited mutations in
either of these genes have increased risks of ovarian and breast cancer; the estimated risk
for breast cancer and mutations in BRCA1 is between 50% to 80% and in BRCA2 is
between 40% and 70%, while the lifetime risk for ovarian cancer with BRCA1 mutations
is about 40%. With mutations in BRCA2 it is about 20% (Garber & Offit, 2005).
Mutations in BRCA2 can also lead to higher incidences of prostate cancer, pancreatic
cancer, and melanoma (Garber & Offit, 2005). These genes are not the only ones that
contribute to a hereditary cancer syndrome.
Just like the BRCA genes have an influence on developing hereditary breast and
ovarian cancer, other genes can be involved in predisposition to cancer syndromes. One
such syndrome, hereditary non-polyposis colorectal cancer (HNPCC) or Lynch
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syndrome, also increases the lifetime risk of ovarian and other cancers (Hunn &
Rodriguez, 2012; Pennington & Swisher, 2012). Lynch syndrome is an autosomal
dominant disorder, which can increase the risk of developing colon cancer, endometrial
cancer, gastric cancer, skin, and nervous system cancers (Hunn & Rodriguez, 2012;
Pennington & Swisher, 2012). In women it most often increases the risk of ovarian
cancer by 12% and patients are usually diagnosed at an early age (Pennington & Swisher,
2012). According to Watson et al. (2001), the mean age of 80 cases with HNPCC that
developed ovarian cancer was 42 years of age and, interestingly, they are more often of
epithelial histology, quite different from those found in BRCA1/2 mutation carriers. The
genes that are affected in people with Lynch syndrome are MLH1, MSH2, MSH6, PMS2
and EPCAM. The first four genes are involved in the mismatch repair system, which is
tasked with repairing errors that occur during DNA replication (Pennington & Swisher,
2012). About 70% of families with Lynch syndrome have mutations in MSH2 or MLH1,
with the rest of families having mutations in PMS2 or MSH6 (Pennington & Swisher,
2012). This syndrome is an example of the important role DNA repair mechanisms can
have on predisposing to cancer.
There are a number of other hereditary cancer syndromes that feature mutations in
different genes. Families with these syndromes can benefit from genetic screening to
identify their risk of cancer, and physicians can be aided by genetic screening to help
them diagnose these syndromes. Examples of such hereditary cancer syndromes include
Cowden syndrome, Li-Fraumeni syndrome, Ataxia telangiectasia, Puetz-Juergens
syndrome, and several others. A table of common hereditary cancer syndromes adapted
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from Garber and Offit (2005), with permission of the American Society of Clinical
Oncology, License 3673710531158, can be found in Appendix A. Briefly, Cowden
syndrome can lead to breast cancer, thyroid cancer, and endometrial cancer among others
and is associated with mutations in the PTEN gene (Garber & Offit, 2005). Li-Fraumeni
syndrome is associated with soft tissue sarcoma, brain tumors, leukemia, and breast
cancer. It is most often correlated with mutations in TP53, BRCA2, and CHEK2 (Garber
& Offit, 2005). Ataxia Telangiectasia is a syndrome that can result in leukemia and
lymphoma and the gene identified to have mutations in these cases is ATM (Garber &
Offit, 2005). There are a number of other hereditary cancer syndromes that support the
framework for this study in that there is a genetic component to cancer.
Conceptual Framework
The first known example of a hereditary cancer syndrome where mutations in a
gene were correlated with cancer susceptibility was hereditary retinoblastoma.
Retinoblastoma is a rare pediatric primary malignant tumor of the eye and accounts for
about 1% of cancers in children (Knudson, 1997). In hereditary retinoblastoma, the
tumors are usually bilateral and if caught early eyesight can be saved in affected children.
Knudson (1971), observed that about 40% of cases occurred in younger children who
often reported a family history of the disease. He suggested that the mutations were to be
found on a gene now known as RB1, for retinoblastoma (Knudson, 1971). Once the gene
was cloned, it was identified that people affected with the disease had germline mutations
in RB1 and many had additional RB1 mutations present in the tumor (Knudson, 1997).
Many people were tested for the presence of mutations in the RB1 gene and treatment
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was undertaken so as to preserve vision. His findings on retinoblastoma led him to derive
the two hit model for cancer causation and presented a paradigm shift in the theory that
mutations in genes can lead to cancer.
The conceptual framework this research is based on is Alfred G. Knudson’s two
mutation theory of cancer causation, which was developed during his work on
retinoblastoma (Knudson, 1971). This theory postulates that there are two types of
cancers, either somatic or hereditary (Knudson, 2002; Ormiston, 1996). In somatic
cancers, or those that arise spontaneously, the mutations occur later in life after some of
the many mitotic divisions introduce errors into the genetic material of cells (Ormiston,
1996). He believed that two mutations would lead to cancer causation and that both
mutations would be a consequence of errors during cell cycle divisions (Knudson, 1971,
2002; Ormiston, 1996). In hereditary cancers, one of the mutations occurs at the time of
fertilization and so every cell in the new fetus will have this mutation. These are referred
to as germline mutations. Once one mutation is present, it is easy for another one to occur
somatically during cell division, leading to cancer (Knudson, 1971, 2002; Ormiston,
1996). The presence of a germline mutation and a somatic mutation represent the two hits
Knudson refers to in his theory.
Most cancers are sporadic and occur due to the influence of environmental factors
(Ormiston, 1996). But hereditary cancers have become an important factor in current
cancer syndromes. It is important to identify individuals who may harbor germline
mutations so that prophylaxis can be implemented for the second mutation to possibly be
prevented.

21
The two-mutation theory of cancer causation is a valid conceptual framework for
this study. Many ovarian cancer cases arise from germline mutations in genes such as
BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, and so on (Pennington & Swisher, 2012).
Many of the patients identified with these mutations are diagnosed with ovarian cancer at
younger ages than their sporadic counterparts and have tumors at different sites
(Ormiston, 1996). Many women with germline mutations who develop ovarian cancer
have a high likelihood of developing tumors in breasts, the pancreas, and other sites, or
develop recurrent tumors (Pennington & Swisher, 2012). Additionally, when analyzing
the tumors for somatic mutations, many tumors appear to have mutations in other genes
such as TP53, a tumor suppressor gene (Greenblatt, Chappuis, Bond, Hamel, & Foulkes,
2001; Pennington et al., 2013b). Many ovarian tumors have mutations in the same gene
as their germline mutations and they have been found to have loss of heterozygosity
(LOH) where the wildtype allele is no longer present and only two mutant alleles are left
(Walsh et al., 2011; Pennington et al., 2013b). This conceptual framework is the basis for
this search for mutations in CHEK1 and CHEK2 in ovarian cancer cases since possible
germline mutations in these activators of DNA damage responses could represent the first
hit of two for cancer causation.
BRCA1 and BRCA2
In the 1990s, two genes were sequenced and identified as breast cancer
susceptibility genes: BRCA1 in 1990 located on chromosome 17q and BRCA2 in 1994
located on chromosome 13q (Ormiston, 1996). These two genes were further identified as
tumor suppressor genes. It was determined that mutations in these genes were responsible
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for about 5% of all yearly breast cancer cases in the United States and for approximately
two thirds of breast cancer cases with a family history of the disease (O'Donovan &
Livingston, 2010; Ormiston, 1996). Additional studies have shown that these genes have
not only been associated with breast cancer but also ovarian cancer. It is thought that
women with mutations in these genes have an increased life time risk of acquiring
ovarian cancer;40% risk for BRCA1 mutation carriers and 20% increased risk for BRCA2
(Ormiston, 1996). BRCA1 and BRCA2 are responsible for most of the cases of hereditary
ovarian carcinoma (Pennington & Swisher, 2012) and according to Jervis et al. (2015),
current estimates for the burden of BRCA1 and BRCA2 mutations in ovarian cancer
patients is 27%.
In a study by Pal et al. (2005), the authors performed genetic testing on 209
women with ovarian cancer and found that 32 women (15.3%) had mutations in either
BRCA1 (20) or BRCA2 (12). Most of the women with BRCA1 or BRCA2 mutations had
previous family history of ovarian or breast cancer, but a small percentage had no known
family history, suggesting another mechanism for mutation.
Another study by Zhang et al. (2011) showed a relatively high frequency of
BRCA1 and BRCA2 mutations similar to those found by Pal et al. (2005). The researchers
screened 1342 women with invasive ovarian cancer for BRCA1 and BRCA2 mutations.
They found that 176 of the samples had mutations in BRCA1 and BRCA2, with 107
women harboring mutations in BRCA1, 67 with mutations in BRCA2, and 2 women with
mutations in both genes (Zhang et al., 2011). The researchers also suggested that different
populations vary in susceptibility to mutations in these genes, and the proportions of
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hereditary ovarian cancer depend on the presence of founder mutations in these genes in
people of a specific ancestry (Zhang et al., 2011). They showed a very high prevalence of
mutations in these two genes in women of Ashkenazi Jewish descent.
The three specific founder mutations in the Ashkenazi Jewish population that are
associated with breast and ovarian cancer are: BRCA1.187del AG, BRCA1.5382insC, and
BRCA2.6174delT, and were previously reported by Roa et al. (1996). These studies
indicate that the prevalence of mutations in these two genes account for a large number of
ovarian cancer cases and that ancestry is a factor given the hereditary nature of these
cancers.
Additionally, besides elevated risk of disease, there are other characteristics
within the disease that are affected by mutations in these genes such as survival,
sensitivity to chemotherapy, and the clinical phenotype of the carcinoma. In a review of
ovarian tumors from 178 BRCA1 mutation carriers and 29 BRCA2 mutation carriers
compared to 235 controls, researchers found that the predominant histology for BRCA1/2
mutation carriers was high grade serous adenocarcinomas, which are most often
associated with poorer outcomes (Lakhani et al., 2004). They also found higher solid
components, which is correlated with necrosis, and also strong staining for P53 protein, a
mediator of apoptosis (Lakhani et al., 2004). Overall they found that these characteristics
were a hallmark of BRCA1 and BRCA2 mutation carriers and resulted in poorer
prognoses.
On the other hand, despite the poorer prognosis when treated early and identified
early, the overall survival of BRCA1/2 mutation carriers is longer than in non-carriers
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because they have better responses to platinum-based chemotherapy and their tumors are
more sensitive to poly-ADP-ribose polymerase (PARP) inhibitors (Yang, Khan, Sun, &
et al., 2011). Yang et al. (2011) found a higher number of cases who had higher
chemotherapy sensitivity rates (100% for mutation carriers and 80% for wildtype) and
higher progression-free, 5-year survival rates (61% vs 25%) than wildtype cases (Yang et
al., 2011). A study by Pennington et al. (2013a) concluded that women with germline
mutations in BRCA1 and BRCA2 as well as other homologous repair pathway genes had
improved survival and response to platinum-based chemotherapy. These data show better
outcomes for mutation carriers.
Many BRCA1/2 mutation carriers can undergo risk-reducing salpingooophorectomy (RRSO) which has proven to reduce mortality in high risk women and has
become the standard of care for women with high risk mutations. A study by Domchek et
al. (2010), found that in women who underwent RRSO compared to women who did not,
the all-cause mortality was reduced from 10% to 3%, the breast cancer specific mortality
was reduced from 6% to 2%, and the ovarian cancer specific mortality was reduced from
3% to 0.4%. Most recently a study by the Gynecologic Oncology Group (GOG) from a
trial in which women with BRCA1 and BRCA2 mutations underwent RRSO, found that
occult cancers were present in 2.6% of high risk women (Sherman et al., 2014). This
emphasizes the importance of knowing your mutation status to pursue risk reduction
efforts. These studies, and the contribution of BRCA1 and BRCA2 mutations to ovarian
cancer, highlight the strong genetic component and familial risk of this disease as well as
the opportunities that genetic testing may give patients and their families.
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Age at Diagnosis
Researchers have demonstrated that ovarian carcinoma diagnosis in mutation
carriers occurs at a younger age than those who are not mutation carriers. Pal et al. (2005)
found that mutation carriers present with disease at a younger age than wildtype cases.
The findings of Pal et al. (2005) regarding age reiterated the results of a previous study
by Risch et al. (2001). In that study, researchers studied BRCA1 and BRCA2 mutation
rates in 515 unselected cases and found a mutation rate of 11.7% (Risch et al., 2001). For
those women with BRCA1 mutations, 80% were younger than 50 at time of diagnosis
(Risch et al., 2001). For BRCA2 only, about 40% of the women with mutations were
younger than 50 at time of diagnosis (Risch et al., 2001). These studies suggest women
are younger when diagnosed with the disease if they are BRCA1 mutation carriers.
Age at diagnosis was also a distinction found when researching specific
populations such as the Ashkenazi Jewish population. Boyd et al., (2000) reported that
women of Jewish origin with ovarian cancer who participated in a retrospective cohort
for BRCA1/2 mutations were significantly younger than women without mutations. The
authors suggested that age at diagnosis could be a predictor for carrying a mutation in the
aforementioned genes.
More recently Alsop et al. (2012) supported Boyd’s suggestion with their
population-based study to determine BRCA1/2 mutation frequencies in ovarian carcinoma
patients. They too found that age of ovarian cancer onset is a strong predictor for carrying
a BRCA1 or BRCA2 mutation. In this study, 22.2% women who carried a mutation in
either gene were 50 years or younger, while only 12.1% were older than 50 (Alsop et al.,
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2012). These results add to the evidence that mutation carriers are usually younger when
they are diagnosed with the disease.
These findings not only apply to mutations in BRCA1 and BRCA2. In a very
recent study by Cunningham et al. (2014), the authors looked at the rate of germline
mutations, somatic mutations, and methylation status in BRCA1 and RAD51C.
Hypermethylation of the promoter region genes resulted in abrogation of their expression
in a similar manner as a loss of function mutation would result in a lack of expression of
a functional gene. These alterations result in a HR deficient (HRD) phenotype, where the
DNA repair by HR is defective. Those women who had an HRD phenotype were of
younger age at time of diagnosis than those without abnormality, demonstrating that
defects in HR repair can result in disease earlier in life.
In addition, women with mutations in mismatch repair genes are generally
younger when they develop ovarian cancer than women without mutations. Pal et al.
(2012) presented their population-based study to determine the frequency of mutations in
mismatch repair genes. Among other findings, they identified a difference in age at
diagnosis of ovarian cancer in three subsets: women with clearly pathogenic mutations,
those with mutations that are predicted to be pathogenic, and those with no mutations in
these genes. The average age of diagnosis of women with pathogenic mutations was of
47.1 years, the age for those with predicted pathogenic mutations was of 53.2 years, and
age of diagnosis for those women with no mutations was 56.1 years (Pal et al., 2012).
Since they identified a range of age at time of diagnosis between 40 and 59 years, they
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recommended that women with mutations and susceptible to HNPCC associated ovarian
cancer should undergo prophylactic salpingo oophorectomy prior to the age of 40.
Overall, these results show that mutation carriers are more likely to be younger at
age of diagnosis regardless of what gene and that determining if mutations in CHEK1 and
CHEK2 are associated with younger age can lead to recommendations for testing at
earlier ages rather than later ages.
Fanconi Anemia-BRCA Pathway and Ovarian Cancer
Fanconi anemia (FA) is a rare inherited disorder that can lead to bone marrow
failure, developmental abnormalities, and childhood cancers such as leukemia (D'Andrea
& Grompe, 2003). It is characterized by increased chromosomal breakage in the presence
of DNA interstrand crosslinking reagents such as diepoxybutane (DEB) (D'Andrea &
Grompe, 2003). Research in the field of FA identified 14 genes that may be responsible
in the inheritance of this disease, and the characteristic of increased chromosomal
breakage, increased sensitivity to interstrand crosslinking reagents, and susceptibility to
cancers suggested that the proteins encoded by these genes may be involved in DNA
repair (Mathew, 2006). Overall, there are 13 genes that have been identified as being part
of the FA pathway that are involved in the disease; among them is the Breast Cancer
Susceptibility gene BRCA2 (D'Andrea & Grompe, 2003; Mathew, 2006). In fact, the first
big correlation between DNA repair and the FA proteins came when the gene known as
FANCD1 was identified to be identical to the tumor suppressor gene BRCA2 (Howlett et
al., 2002). Since that study FANCD1 is mostly referred to as BRCA2 and hardly ever as
FANCD1 (Mathew, 2006). This also led to renaming the pathway from FA pathway to
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FA-BRCA pathway to emphasize the relationship between Fanconi anemia and breast
cancer.
In 2002, scientists in Dr. D’Andrea’s laboratory were able to show that cells
derived from patients with two different types of FA groups, FA-B and FA-D1, had
biallelic mutations in BRCA2, which led to shortened BRCA2 proteins and faulty DNA
repair as determined by Mytomycin C (MMC) sensitivity (Howlett et al., 2002). They
complemented the FA-D1 cells with an unmutated copy of BRCA2 and were able to
restore the wild-type phenotype in those cells (Howlett et al., 2002). Additionally they
were able to determine that the BRCA2 mutations they found in those cells were present
in the patients from which the cells originated and also segregated well within the family
of the patient leading to the conclusion that BRCA2 was responsible for the FA in these
patients (Howlett et al., 2002). Howlett et al. (2002) therefore established that biallelic
mutations in BRCA2 cause FA and monoallelic mutations can lead to breast and ovarian
cancer.
Because biallelic mutations had not been found in BRCA1 that would lead to FA,
it is not considered a FA gene, but it is thought to be a very important player within the
FA-BRCA pathway (D'Andrea & Grompe, 2003). This pathway is involved in DNA
repair through HR, one of the main mechanisms to repair double stranded breaks (DSB)
in DNA with very few errors (D'Andrea & Grompe, 2003; Mathew, 2006). When DNA
becomes damaged, the proteins ATR and ATM kinases activate the FA core proteins to
form a complex of 8 proteins which then monoubiquitinates FANCD2 and FANCI
(D'Andrea & Grompe, 2003; Mathew, 2006). This complex is then recruited to the site of
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DNA damage and recruits 3 other FA proteins (FANCD1, aka BRCA2, FANCN, and
FANCJ). These proteins then form a complex with BRCA1 and interact with a number of
proteins that have been identified as DNA repair associates and repair the damaged DNA
via HR (Mathew, 2006). In HR, the DNA is repaired by aligning homologous sequences
of DNA (D'Andrea & Grompe, 2003). The figure in Appendix B shows a schematic of
the FA-BRCA pathway and the genes associated with this pathway in DNA repair. More
recently it has been shown that the FA pathway interacts with other DNA repair pathways
since there is formation of complexes with numerous other proteins such as NBN, BLM,
and ATR (Thompson, Hinz, Yamada, & Jones, 2005).
As mentioned previously, BRCA1 was not considered a FA pathway gene per se,
since no biallelic mutations in the gene were found in any FA patients. But a recent case
report by Domcheck et al. (2013), identified a woman with ovarian cancer who had
biallelic mutations in BRCA1. The mutations were a known deleterious mutation,
BRCA1.c2457delC, and a variant of unknown significance (VUS), BRCA1.V1736A,
which the authors suggested to be deleterious (Domchek et al., 2013). They showed that
this suspected VUS resulted in a BRCA1 protein with a mutated BRCT (BRCA1 Cterminus) domain, which had a lower affinity of binding to DNA damage response
associated proteins and reduced localization to damaged DNA (Domchek et al., 2013).
This patient was found to have a FA-like syndrome in addition to ovarian cancer, but
passed away before the researchers could do specific FA testing (Domchek et al., 2013).
These findings show the importance of BRCA1 in the FA pathway and also that biallelic
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mutations could lead to a genetic syndrome that encompasses hereditary ovarian cancer
with developmental defects and FA like symptoms.
A number of genes other than BRCA1 and BRCA2 involved in the FA-BRCA
pathway or are known associates of this pathway have been associated with increased
susceptibility to breast cancer and ovarian cancer. ATM encodes for a protein kinase,
involved in the DNA damage response, and it activates checkpoint signaling in response
to damage. Just like for BRCA2 and FA, people with biallelic mutations in ATM suffer
from ataxia telangiectasia, a disease characterized by ataxias in the brain,
immunodeficiency, and an increased risk of leukemia and lymphoma (Pennington &
Swisher, 2012). In addition, these patients are also at increased risk of ovarian, breast,
and gastric cancers (Pennington & Swisher, 2012).
Most recently, a group led by Dr. Rahman found that ATM was a breast cancer
susceptibility gene in people who carry one mutation in the gene (Renwick et al., 2006).
They sequenced 443 familial breast cancer cases and 521 controls and they found 2.04%
of cases carrying deleterious mutations that could result in premature shortening of the
protein or in exon skipping (Renwick et al., 2006). The rate of ATM mutations in controls
was only 0.4% (Renwick et al., 2006). This provided strong evidence for a role of ATM in
breast cancer.
Other genes identified as breast cancer susceptibility genes include CHEK2,
BARD1, MRE11A, NBN, RAD50, RAD51C, BRIP1, and PALB2 (Pennington & Swisher,
2012). It was thought that only breast cancer would be affected by mutations in non
BRCA genes and that increased risk of ovarian cancer was only due to mutation in the
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two BRCA genes. But this notion has changed and several other genes in the DNA
damage response pathway or associated with it have been identified as increasing the
susceptibility to ovarian cancer.
PALB2 was recently identified as harboring mutations in ovarian cancer patients.
This gene is also known as FANCN and is an important contributor of the FA pathway. A
study by Casadei et al. (2011), which initially just investigated breast cancer cases,
showed that in 18 families of the 33 studied, family members with ovarian cancer had
PALB2 mutations. They found that people with a PALB2 mutation had a 1.3 fold higher
chance of having a relative with ovarian cancer (Casadei et al., 2011). While the number
was not statistically significant due to the small sample size, it still showed that PALB2
could be a susceptibility gene for ovarian cancer.
Further support for PALB2 as an ovarian cancer susceptibility gene was provided
by Dansonka-Mieszkowska et al. (2010)in Poland, who found that truncating mutations
in PALB2 were present 7 times more often in ovarian cancer cases (2/339) than in
controls (1/1310). These studies present a strong case for PALB2 mutations as possible
hits for ovarian cancer.
Another FA main complex gene, BRIP1 (also known as FANCJ), was also
identified as a susceptibility gene for ovarian cancer. Rafnar et al. (2011) performed two
studies in two different populations. They started with a whole genome sequencing
project in Iceland, where they assessed 457 Icelanders (Rafnar et al., 2011). They found a
rare mutation in BRIP1, c.2040_2041insTT, that was associated with an increased risk of
ovarian cancer, with an OR = 8.13 (Rafnar et al., 2011). They performed further research
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and sequenced BRIP1 in a Spanish cohort of 144 cases and 1,780 controls (Rafnar et al.,
2011). They found another rare frameshift in BRIP1 (BRIP.c1702_1703del) in two of the
cases and in only one control, resulting in an OR = 25 (Rafnar et al., 2011). These results
suggest that BRIP1 can play a role in susceptibility to ovarian cancer.
More recently, RAD51C and RAD51D, two important genes in DNA damage
repair and HR, have been implicated in contributing to ovarian cancer. Meindl et al.
(2010), initially described a link between RAD51C and ovarian cancer; they found
mutations in RAD51C in 6 families out of 480 that had breast and ovarian cancer and
were screened for that gene, while in other 620 families with only breast cancer and
2,912 healthy controls there were no mutations in RAD51C (Meindl et al., 2010). This
made for a strong point for this gene’s role in ovarian cancer.
In a Finnish study where they screened breast and/or ovarian cancer patients and
families for RAD51C, they found that mutations in RAD51C were most often associated
with “an increased risk of familial breast and ovarian cancer (OR 13.59, 95% CI 1.89–
97.6, P =0.026 compared with controls), but especially with familial ovarian cancer in the
absence of breast cancer (OR 213, 95% CI 25.6–1769, P = 0.0002) and also with
unselected ovarian cancer (OR 6.31, 95% CI 1.15–34.6, P = 0.033), with a significantly
higher mutation rate among the familial cases (two out of eight, 25%) than the unselected
ovarian cancer cases (4 out of 409, 1%) (OR 33.8, 95% CI 5.15–221, P = 0.005)”
(Pelttari et al., 2011, p. 3278). They also found that all ovarian cancer cases occurred in
those who were less than 60 years old, suggesting that ovarian cancer cases with
mutations in this gene are younger than patients with ovarian cancer that do not have
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mutations (Pelttari et al., 2011). These results presented further evidence for RAD51C’s
involvement in ovarian cancer.
Loveday et al. (2012) also reported a study in which they sequenced RAD51C in
272 ovarian cancer cases and 1,156 population controls and found that about 1% of
ovarian cancer cases harbored germline mutations in that gene. In addition they also
found that ovarian cancer cases with mutations in RAD51C were diagnosed at younger
ages, one of the patients as young as 43 (Loveday et al., 2012). RAD51C is currently
considered a gene for ovarian cancer susceptibility.
RAD51D was also implicated as an ovarian cancer gene by the same group that
investigated the relationship of ovarian cancer with RAD51C. Loveday and colleagues
(2011) investigated RAD51D, another paralog for RAD51, prior to their findings with
RAD51C. They found 8 damaging mutations in 911 individuals from breast and ovarian
cancer families, and only 1 in 1,060 controls (Loveday et al., 2011). They found the
association to be stronger in ovarian cancer since 3 of the mutations were found in the 59
families that had 3 or more individuals with ovarian cancer most of which were under 60
years of age (Loveday et al., 2011). The study led by Loveday (2011) established a
relative risk for ovarian cancer for those people with RAD51D mutations to be 6.3, while
for breast cancer the relative risk was only 1.32, leading them to the conclusion that
RAD51D is predominantly an ovarian cancer risk gene.
Another study led by Wickramanyake, found that out of 360 ovarian, fallopian
tube, and peritoneal cancer patients, three carried loss of function (LOF) mutations in
RAD51D (Wickramanyake et al., 2012). When the researchers sequenced 449 women and
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10 men with breast cancer for RAD51D mutations, they were not able to find any, leading
to the conclusion that RAD51D is a gene that, if mutated, can confer risk for ovarian
cancer (Wickramanyake et al., 2012).
Taken together, this research shows that BRCA1 and BRCA2 are not the only
genes conferring risk for ovarian cancer but other genes involved within the FA-BRCA
pathway or associated with it or with DNA repair can confer risk for ovarian cancer.
Jervis et al. (2015) reported that approximately 10% of ovarian cancer cases can be
attributed to rare variants in other genes such as the MMR genes, RAD51C, RAD51D,
and BRIP1. In addition, like it is the case for people with mutations in BRCA1 and
BRCA2, the age of diagnosis for ovarian cancer cases with mutations in some FA genes
are younger than patients without mutations (Loveday et al, 2012, Norquist et al., 2013,
Pelttari et al., 2011). Continued research in genes associated with DNA repair is of great
importance to determine their possible association with ovarian cancer.
CHEK1 and CHEK2
The following discussion will include mention of genes CHEK1 and CHEK2 and
the proteins CHEK1 and CHEK2. Per HGNC ( Human Genome OrganizationGene
Nomenclature Committee) guidelines, the gene names will be italicized and protein
names will be set in the standard font (Gray, Gordon, Seal, Wright & Bruford, 2013).
The genes CHEK1 and CHEK2 encode the proteins CHEK1 and CHEK2, two
serine threonine kinases that are required for cell cycle arrest in response to DNA damage
and modulate the activation of different DNA repair pathways (National Center for
Biotechnology Information , 2014a, 2014b; Reinhardt & Yaffe, 2009). They are
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structurally unrelated but perform similar functions. These kinases receive signals from
two other kinases, ATM and ATR, which are activated in response to DNA damage
(Reinhardt & Yaffe, 2009). It is thought that for the most part the protein ATM activates
CHEK2 in response to double-stranded breaks (DBS) and ATR activates CHEK1 in
response to single stranded breaks (Reinhardt & Yaffe, 2009), but ATM can also interact
with CHEK1, and CHEK1 can also be involved in DBS repairs. The activation of these
checkpoint kinases represents a DNA surveillance program, which ensures that there is
faithful transmission of the DNA and that the integrity of the DNA is conserved during
different cell cycles (Reinhardt & Yaffe, 2009). These checkpoint kinases prevent the
progression of damaged DNA further into the cell cycle and even activate apoptosis or
programed cell death if the damage is beyond repair (Reinhardt & Yaffe, 2009).
CHEK2
CHEK2 is activated by ATM, which phosphorylates CHEK2 at threonine residue
68 (Dai & Grant, 2010). Upon phosphorylation by ATM, CHEK2 homodimerizes and
finally fully activates by the “trans-phosphorylation” of two of its threonine residues, 383
and 387 (Dai & Grant, 2010). It then phosphorylates the protein Cdc25C and confines it
to the cytoplasm where it cannot activate other proteins to move ahead through the
different phases of mitosis, in this case from M (mitotic) phase to G2 (interphase second
gap) phase (Stolz, Ertych, & Bastians, 2011). Hence, CHEK2 leads to cell cycle arrest
prior to G2. It is also able to promote cell cycle arrest at G1 (interphase first gap) phase
by interacting with p53, a tumor suppressor gene (NCBI, 2014b). It also interacts with
p53 to initiate apoptosis when the DNA is beyond repair (Stolz et al., 2011). CHEK2 also
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phosphorylates BRCA1 on serine residue 988, which in turn allows BRCA1 to become
soluble and proceed to become involved in the FA-BRCA pathway mediated HR repair
(Stolz et al., 2011).
The implication of CHEK2 as a cancer susceptibility gene has been reported by
several groups especially in the field of breast cancer research. Several specific alleles
have been associated with specific populations and with specific cancers. In a study by
Cybulski et al. (2004), the authors reported an analysis they performed on 4,000 controls
and 4,008 cancer cases, for which many different cancer sites were represented (Cybulski
et al., 2004). They looked for three specific founder alleles for CHEK2:
CHEK2.1100delC, CHEK2.IVS2+1G->A and CHEK2.I157T (Cybulski et al., 2004).
They established positive associations with thyroid (OR = 4.9), breast (OR = 2.2), and
prostate cancer (OR = 2.2) and the two truncating alleles (CHEK2.1100delC and
CHEK2.IVS2+1G->A) (Cybulski et al., 2004). For the specific missense, they found
strong associations for increased risks of breast (OR = 1.4), colon (OR = 2.0), kidney
(OR = 2.1), prostrate (OR = 1.7), and thyroid cancer (OR = 1.9) (Cybulski et al., 2004).
The odds ratio for that specific allele in ovarian cancer was 1 (Cybulski et al., 2004),
which doesn’t support a possible connection to ovarian cancer. The authors believe that
this gene is a multiorgan susceptibility gene, but because they only tested three alleles
their study is not robust in regard to a possible association to ovarian cancer.
Further research from this group analyzed the presence of these alleles in Polish
ovarian cancer patients compared to controls. What they found was that the same
missense, CHEK2.I157T, resulted in a positive association with ovarian cancer patients
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that had low grade invasive tumors (OR = 2.5) (Szymanska-Pasternak et al., 2006). They
followed up with a small sample of Russian patients and had similar findings, (OR = 2.7),
for that specific missense in patients with borderline ovarian tumors, which are noninvasive ovarian tumors (Szymanska-Pasternak et al., 2006). This study shows a small
association between CHEK2 and borderline ovarian tumors but they only focused on one
specific mutation in the gene as opposed to looking at mutations within the whole gene.
One particular allele that has been reproducibly associated with breast cancer is
CHEK2.1100delC. It was positively associated with breast cancer in the study by
Cybulski et al. (2004). It was also the focus of a meta-analysis performed by a group in
Denmark that reviewed the literature to identify 26,000 patients and 27,000 controls
analyzed for this allele. They found that there was an “aggregated odds ratios of 2.7 (95%
CI, 2.1 to 3.4) for unselected breast cancer, 2.6 (95% CI, 1.3 to 5.5) for early-onset breast
cancer, and 4.8 (95% CI, 3.3 to 7.2) for familial breast cancer” (Weischer, Bojesen,
Ellervik, Tybjærg-Hansen, & Nordestgaard, 2008, p.542). This led them to calculate a
cumulative risk for breast cancer for people with this mutation to be 37%, with a 95% CI
of 26% to 56% (Weischer et al., 2008). Furthermore, individuals who carry this specific
mutation, CHEK2.1100delC, are at higher risk for bilateral breast cancer and male breast
cancer (Mellemkjær et al., 2008). A similar risk for ovarian cancer has not been
calculated.
There are other alleles that have been found to confer susceptibility to breast
cancer, such as a CHEK2.S428F variant found to increase breast cancer risk by 2 fold in
women of Ashkenazi Jewish descent, two other variants in women of Italian descent, and
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one new variant in a high risk breast cancer family from France (Escudie et al., 2010;
Manoukian et al., 2011; Shaag et al., 2005). One study analyzed whether the variant
CHEK2.1100delC was associated with ovarian cancer in 486 cases and 323 controls, but
found no correlation, possibly because they only looked at this specific mutation and not
at the entire gene (Baysal et al., 2004). Based on the evidence from these previous
studies, it is important to find out if CHEK2 is an ovarian cancer susceptibility gene like
it is for breast cancer.
Ovarian cancer susceptibility has not been clearly established, but there have been
reports of rare variants in CHEK2 in ovarian cancer patients. In a Next-Generation
sequencing study, Minion et al. (2015), sequenced 19 genes in women with a personal
history of breast cancer (353 women), ovarian cancer (466 women), and breast and
ovarian cancer (92 women). Mutations in CHEK2 were found in 7% of women with a
history of ovarian cancer and in 5% of women with both a history of ovarian and breast
cancer (Minion et al, 2015). The authors only reported rates and did not compare cases
versus controls. This study supports the necessity to clearly determine whether there is an
association between CHEK2 mutations and ovarian cancer.
Of especial interest is research by Ow et al. (2014), who performed analysis on
clinical data from The Cancer Genome Atlas (TCGA), and found that in patients
diagnosed with High Grade Serous Ovarian Cancer (HG-SOC) with CHEK2 mutations,
the survival prognosis was poor. These mutations may be associated with resistance to
existing chemotherapy (Ow et al., 2014). This research contrasts the Pennington et al.
(2013a) research that in 3 out of 367 women with ovarian cancer with mutations in
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CHEK2, there was an association with improved survival and response to platinum-based
chemotherapy in women with mutations in homologous repair (HR) genes (Pennington et
al., 2013a). These differences may be related to the grade and histology of the ovarian
cancer, but it certainly supports the notion that in order to appropriately manage treatment
for ovarian cancer it is important to know if mutations in CHEK2 are present.
CHEK2 is activated by ATM and interacts directly with BRCA1. It is an integral
part of activating the DNA damage repair pathway and therefore the lack of a functioning
CHEK2 protein due to mutations in the gene would result in a lagging DNA damage
response. The research in this study may lead to the analysis of the entire gene in ovarian
cancer patients, rather than just looking at specific mutations as in previous published
papers. Such a global view of possible candidate variants would give a clearer picture of
whether CHEK2 is truly an ovarian cancer susceptibility gene or not.
CHEK1
The protein CHEK1 is activated by ATR and to a lesser extent by ATM (Dai &
Grant, 2010). ATR phosphorylates CHEK1 at either the serine residue 317 or 345,
activating CHEK1 and allowing it to phosphorylate Cdc25A/C, leading to cell cycle
arrest in S or G2 phases of the cell cycle (Dai & Grant, 2010). CHEK1 plays a dominant
role in replication initiation during S phase and is an amplifier of the DSB response
signaling mediated by ATM and CHEK2 (Dai & Grant, 2010). CHEK1 is also an
important protein in the delaying of anaphase in cells with spindle defects, and during
G2/M phase it helps with stabilization and proteasomal degradation (Dai & Grant, 2010).
In addition, during DNA damage and repair, CHEK1 targets kinases important for DNA
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repair. CHEK1 dependent phosphorylation of RAD51 induces HR and its
phosphorylation of FANCE (one of the FA proteins) is also critical for FA-BRCA
mediated repair (Dai & Grant, 2010).
In order to show that the protein CHEK1, encoded by CHEK1, is required for HR
repair, Sorensen et al. (2005), were able to inhibit the function of the CHEK1 protein in
Chinese Hamster cells (CHO cells), by way of using small interfering RNAs that inhibit
the translation of CHEK1 message into protein. They then induced replication associated
Double Strand Breaks (DSB), which normally initiates HR repair, by adding hydroxyurea
and camptothecin to the media (Sorensen et al., 2005). They determined the survival of
cells after DNA damage and replication arrest. They saw that cells proficient in HR repair
had poor survival when CHEK1 was inhibited and they also found and increase in DSB
(Sorensen et al., 2005). They were also able to show that CHEK1 interacts with RAD51
in order to induce HR repair. Cells where the threonine residue 309 was mutated on
RAD51, the site of CHEK1 phosphorylation, had increased sensitivity to hydroxyurea
due to the inability to initiate HR repair (Sorensen et al., 2005). This paper highlights the
importance of CHEK1 protein in the pathway for DNA repair, because cell survivability
was reduced and there was an increase in double strand breaks when CHEK1 function
was abrogated.
Another study by Guervilly et al. (2008) showed that inhibition of CHEK1 can
lead to reduced monubiquitination of FANCD2, an important step within the FA-BRCA
damage repair pathway (Guervilly, Macé-Aimé, & Rosselli, 2008). They demonstrated
that mitomycin C (a DNA crosslinker) sensitivity was reduced in cells where the
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ATR/CHEK1 activation was inhibited, suggestive of a central role of CHEK1 in the
arrest of the G2 cell cycle (Guervilly et al., 2008). These functions of the protein encoded
by the gene CHEK1 show the gene’s importance within the DNA repair pathways and
that any mutations could lead to a shortened protein with loss of function.
Finally, there have also been suggestions that the protein BRCA1, one of the
important modulators of the FA-BRCA pathway, interacts with CHEK1 protein. A report
by Yarden et al. (2002), showed that activation of CHEK1 in response to ionizing
radiation was only possible when the BRCA1 protein was being expressed by measuring
CHEK1 kinase activity in cells that were expressing BRCA1 or not. They were also able
to show that BRCA1 interactions with CHEK1 affect G2/M cell cycle arrest by showing
that cells expressing BRCA1 and CHEK1 proteins move from G2 to M after radiation
damage, compared to cells that have these proteins inhibited (Yarden, Pardo-Reoyo,
Sgagias, Cowan, & Brody, 2002). Their results suggested that BRCA1 involvement in
cell cycle arrest is mediated by its interaction with CHEK1 (Yarden et al., 2002). The
research above shows clearly the importance of CHEK1 to the DNA damage response in
cells; cells lacking a proper functioning CHEK1 protein are deficient in fixing double
strand breaks and don’t survive well those insults. Clearly CHEK1 plays an important
role in damage repair and interacts with proteins in the FA-BRCA pathway, therefore
CHEK1 gene is a good candidate as a cancer susceptibility gene, like some of the
members involved in that pathway such as ATM, RAD51D, RAD51C, PALB2, and BRIP1
(see Appendix B), many of which interact directly with BRCA1 as CHEK1 does.
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There is little evidence to associate CHEK1 with cancer because not too many
studies have looked at CHEK1 specifically. A few studies have used genome wide
association studies (GWAS) where they looked at common single nucleotide
polymorphisms (SNPs) over a span of several genes including CHEK1 in breast cancer
cases but these were inconclusive (Haiman et al., 2008; Pooley et al., 2008). Because
GWAS only identify common SNPs and not the whole gene, they cannot detect rare
mutations or deletions that are potentially associated with disease.
Another study by Lin et al. (2013) also investigated common SNPs in ATR and
CHEK1 in breast cancer patients and found that these common alleles were not
implicated in conferring risk to breast cancer, but since they looked at only common
alleles they could not determine whether rare alleles could be involved (Lin et al., 2013).
This underscores the need for an approach that targets the whole gene rather than
common SNPs that are found in many people.
A Finnish study investigating national breast cancer families took the approach of
looking at large genomic rearrangements in the genes BRIP1 and CHEK1 and were
unable to uncover any large insertions or deletions (Solyom, Pylkäs, & Winqvist, 2010).
The lack of findings could be due to the fact that they had a small cohort of only 111
cases.
These reports are suggestive of a low chance of the CHEK1 gene being a possible
cancer associated gene at least in breast cancer, but there is some evidence that mutations
in this gene are present at least in colorectal and endometrial cancers. Researchers in Italy
performed a small study in which they analyzed colon cancers and endometrial cancers
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for the presence of CHEK1 mutations and found frameshift mutations in 1 out of 10
colon cancers and in 2 of 17 endometrial cancers (Bertoni et al., 1999). They did not go
any further than that and unfortunately did not analyze whether these mutations were also
present in the germline or whether they were only somatic mutations. Yet this data
presents initial evidence for a possible implication of CHEK1 in cancer.
Pennington et al. (2013a) reported that they found a germline mutation in CHEK1
in 1 of 367 subjects, in addition to 87 other mutations in HR genes tested by NextGeneration sequencing. They did not compare the rates to controls and therefore where
not able to associate this rare variant in CHEK1 with ovarian cancer within their cohort
(Pennington et al, 2013a). Women with mutations in HR genes had significantly better
survival than those without mutations in and had better response to platinum-based
chemotherapy (Pennington et al., 2013a). Therefore, establishing whether mutations in
CHEK1 are associated with ovarian cancer still remains to be elucidated. Knowing
whether mutations are present in CHEK1 or any of the HR genes can not only inform for
risk reduction but also help manage therapy.
Kumar et al. (2013), performed a “Boolean logic framework” to rank genes for
association with ovarian cancer (Kumar, Breen, & Ranganathan, 2013). They mined the
literature and relied on functional characteristics of other cancer susceptibility genes and
CHEK1 is among the genes they found to possibly have an important role in ovarian
cancer (Kumar et al., 2013).
Most recent studies have looked at CHEK1 protein inhibitors as potential
adjuvants and single agents for cancer chemotherapy (Kim, Min, Wright, Goldlust &
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Annunziata, 2014; Kim, James & Annunziata, 2015). The addition of CHEK1 protein
inhibitor increases the response of BRCA1/2 or TP53 mutation positive ovarian
carcinoma cells to chemotherapeutic compounds, such as Topotecan and others (Kim,
Min, Wright, Goldlust & Annunziata, 2014; Kim, James & Annunziata, 2015). Results
like this have led to the implementation of a phase 2 clinical trial to determine the effects
of CHEK1 protein inhibitors in women with ovarian cancer (Kim, James & Annunziata,
2015). These results add to the question of the role of genetic mutations in CHEK1 and
the development of ovarian cancer. A non-functioning CHEK1 protein, resulting from a
mutation in the CHEK1 gene could be protective if indeed CHEK1 protein inhibitors
result in a better response to chemotherapeutic agents. A better understanding of the
association between a mutated CHEK1 and ovarian cancer, whether positive or negative,
can not only have implications for reduction of disease risk but also management of
chemotherapy during disease. Further research with a whole gene approach to determine
whether CHEK1 is an ovarian cancer susceptibility gene still needs to be undertaken. The
research proposed will elucidate the effect of mutations in CHEK1 (with a whole gene
approach) on ovarian cancer.
Next-Generation Sequencing and BROCA
Most of the studies that have identified susceptibility genes to date were done by
Sanger sequencing specific genes or by identifying susceptibility loci by genome wide
association studies (Manoukian et al., 2011; Walsh et al., 2006). But with the advent of
new, highly efficient technologies, the trend has shifted toward next-generation
sequencing approaches involving targeted capture and massively parallel sequencing
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approaches of several genes at once (Walsh et al., 2011). These techniques allow the
users to sequence a large number of different genes at once in a large cohort of people in
a very quick time period (Walsh et al., 2011). It also allows for a lower cost method that
enables people to get a deep coverage within the genome and accurate mutation calls.
Walsh et al. (2010), developed a genomic capture and massively parallel
sequencing approach, they called BROCA, that allowed them to sequence 21 genes in
tandem in 20 women that were diagnosed with breast and ovarian cancer and who had
previously been identified as mutation carriers by Sanger sequencing (Walsh et al.,
2010). The genomic DNA is hybridized to capture oligonucleotides that span the genes or
regions of interest and then sequenced on a next-generation sequence analyzer (Walsh et
al., 2010). They were able to find all mutations that were present in the samples and
demonstrate that this method can be applied to comprehensively test for mutations in
several genes and several patients at once (Walsh et al., 2010).
In a follow up study, the group used BROCA to analyze germline DNA from 360
ovarian cancer cases and sequenced 21 genes concurrently (Walsh et al., 2011). They
found that about 24% of these ovarian cancer patients had mutations in different genes
(Walsh et al., 2011). The mutations identified were in BRCA1 and BRCA2, about 18% of
cases had mutations in these two genes (Walsh et al., 2011). But, interestingly, 6% of
cases carried mutations in other genes including BARD1, BRIP1, CHEK2, MRE11A,
MSH6, NBN, PALB2, RAD50, RAD51C, and TP53 (Walsh et al., 2011). While BRIP1,
PALB2, MSH6, and RAD51C had previously been associated as risk conferring genes for
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ovarian cancer, the other 6 had not (Walsh et al., 2011). Most of these genes are involved
in the DNA damage response.
Most recently Harrell et al. (2013) reported at the 63rd annual Meeting of The
American Society of Human Genetics in Boston that researchers in Dr. Elizabeth
Swisher’s lab at the University of Washington expanded the study initially undertaken by
Walsh et al. in 2011. The BROCA gene panel was extended to include 52 genes, some
within the FA-BRCA pathway or associated genes and genes in related damage response
pathways (Harrell et al., 2013). The researchers tested 1,418 cases with ovarian, fallopian
tube, or peritoneal carcinoma. They found that 15.7% of patients carried mutations in
BRCA1 and BRCA2, 10.3% in BRCA1, and 5.4% in BRCA2. 6.3% of cases were
harboring mutations in other DNA repair genes which are known or suspected to cause
ovarian cancer (Harrell et al., 2013). Overall, they found 313 mutations in 1,418
individuals, which represented 22% of the cohort (Harrell et al., 2013). BRCA1 and
BRCA2 accounted for about 73% of all mutations while 27% of mutations were found in
other genes (Harrell et al., 2013). The next most commonly mutated gene was BRIP1
with 6% of mutations, followed by RAD51C, RAD51D, PALB2, and ATM, each gene
harboring almost 3% of mutations within the cohort (Harrell et al., 2013). Mutations in
the Lynch syndrome genes (MSH6, MSH2, MLH1, PMS2), all taken together accounted
for 1.6% of mutations (Harrell et al., 2013). There were also a number of truncating
mutations in some genes that had not been previously associated with breast or ovarian
cancer, which may be good candidates for association with ovarian cancer. These
included ATR and RBBP8, also known as CTIP (Harrell et al., 2013). These genes are
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attractive candidates for ovarian cancer susceptibility because of their central roles within
the FA-BRCA pathway and the minimal number of loss of function mutations reported in
public databases (Harrell et al., 2013).
This research was also supported by a recent study by Minion et al., (2015) where
they performed next-generation sequencing on 19 genes on DNA from ovarian cancer
patients, breast cancer patients, and patients with a history of both. Their findings looked
beyond BRCA1 and BRCA2 at rates in genes that have previously been identified as
ovarian and breast cancer susceptibility genes such as BRIP1 (15%), NBN (6%), PALB2
(6%), BARD1 (3%) and others (Minion et al., 2015). This research brings to light how
novel sequencing techniques can aid in researching novel cancer susceptibility genes and
that identification of hereditary risk for ovarian cancer requires assessment of many genes
in all cases, which can be done effectively with cancer gene panels such as BROCA. This
new technology was used to assess mutations in CHEK1 and CHEK2 and helped identify
whether these genes can also be considered candidate genes for ovarian cancer.
Summary
It has been shown that one of the most important risk factors for ovarian cancer is
familial risk (Check, 2006; Goff, Mandel, Muntz, & Melancon, 2000; Pennington &
Swisher, 2012). Certain genes will acquire mutations that will increase a person’s
likelihood of developing ovarian cancer (Dansonka-Mieszkowska et al., 2010; Susan M.
Domchek et al., 2013; Loveday et al., 2011; C. Loveday et al., 2012; Renwick et al.,
2006; Walsh et al., 2011). Many of these genes are found to be important players in DNA
repair pathways and are considered tumor suppressor genes (D'Andrea, 2013; D'Andrea
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& Grompe, 2003; Pennington & Swisher, 2012). Novel sequencing techniques have made
it easier to identify mutations in cases and controls in many genes at once, rather than just
one gene at a time (Harrell et al., 2013; Walsh et al., 2011; Walsh et al., 2010). These
techniques will allow for the identification of other candidate genes that may increase the
risk for ovarian cancer. CHEK1 and CHEK2 are two genes that, due to their function and
associated with known risk genes and DNA repair pathways, are considered good
candidates for ovarian cancer susceptibility (Cybulski et al., 2004; Huang et al., 2008;
Kumar et al., 2013). The evidence to date for an association between these two genes and
ovarian cancer is sparse and additional research elucidated their roles in cancer risk.
Chapter 3 contains information about the study design, including a description of
the variables, the sample size, and data generation techniques, as well as a summary of
the chapter and plans for how this research will be disseminated.
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Chapter 3: Research Method
Introduction
This research investigated whether mutations in the genes CHEK1 and CHEK2
are associated with ovarian cancer and identifiable as candidate genes for this disease
within this cohort. It also investigated whether there was an association between age at
diagnosis and mutations in these genes. This chapter describes the participants in this
study, the tools used to ascertain mutations in the probands and controls, as well as the
statistical analysis that was used to establish a correlation between disease and mutations
in each gene. Finally, it describes the ethical protections for participants and how the
resulting data will be disseminated to the public.
Previous genetic studies have shown that a myriad of genes are associated with
cancer when they harbor loss of function mutations (Loveday et al., 2012; O'Donovan &
Livingston, 2010; Pelttari et al., 2011; Szymanska-Pasternak et al., 2006;
Wickramanyake et al., 2012). There is some published research correlating CHEK1 and
CHEK2 genes to ovarian cancer, but clear evidence has not been presented to date
(Cybulski et al., 2004; Szymanska-Pasternak et al., 2006; Vahteristo et al., 2001; Walsh
et al., 2011;Pennington et al., 2013a; Minion et al. 2015). This research helped elucidate
the role of CHEK1 and CHEK2 in predisposition to cancer and whether this phenomenon
corroborates Knudson’s two hit theory of cancer causation. The framework of this study
was based on Knudson’s (2002) two-hit theory of cancer causation, which states that for
cancer to occur there must be a germline mutation in a gene and then another somatic
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mutation within the tumor cells. This research exposed CHEK1 and CHEK2 as potential
first-hit mutation bearers.
This research constituted a secondary data analysis using data provided by Dr.
Elizabeth Swisher at the University of Washington, Seattle, WA as well as publicly
available data from the Exome Variant Server and from a paper by Kanchi et al. (2014).
No original data were collected for this study. Patients of Dr. Swisher and other
gynecologic oncologists at the University of Washington consented to be included in a
number of different studies to support the university’s gynecologic oncology tissue bank.
DNA from these probands underwent BROCA, a massively parallel targeted sequencing
approach. Identified mutations by Next-generation sequencing were validated by Sanger
sequencing. Data for mutations in controls was also available from previous studies that
were part of the Women’s Health Initiative and the Exome Variant Server and acquired
by whole-exome sequencing. Data from controls have also been published by Kanchi et
al. (2014). The data included information on mutations identified in the cohort, which in
turn allowed for ascertaining mutation rates in cases versus controls. The comparison of
mutation rates helped determine whether there was an association between ovarian cancer
and mutations in each gene. This research also determined whether there was any
correlation between CHEK1or CHEK2 mutations and ovarian cancer diagnosis as well as
age at diagnosis.
Research Questions
The research questions evaluated in this study are as follows:
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H1: Are CHEK2 mutated alleles associated with ovarian cancer?
H01: There are no CHEK2 mutated alleles associated with ovarian cancer.
Ha1: CHEK2 mutated alleles are associated with ovarian cancer.
H2: Are CHEK1 mutated alleles associated with ovarian cancer?
H02: There are no CHEK1 mutated alleles associated with ovarian cancer.
Ha2: CHEK1 mutated alleles are associated with ovarian cancer.
H3: Are CHEK1 mutated alleles associated with younger age (<60 years of age) at
diagnosis in ovarian cancer cases?
H03: There is no association between younger age at diagnosis and CHEK1
mutations in ovarian cancer cases.
Ha3: Mutated alleles in CHEK1 are associated with younger age (<60 years of
age) at diagnosis in ovarian cancer cases.
H4: Are CHEK2 mutated alleles associated with younger age (<60 years of age) at
diagnosis in ovarian cancer cases?
H04: There is no association between younger age at diagnosis and CHEK2
mutations in ovarian cancer cases.
Ha4: Mutated alleles in CHEK2 are associated with younger age (<60 years of
age) at diagnosis in ovarian cancer cases.
Participants
The cases included 587 prospectively enrolled women who underwent primary
surgery for ovarian, fallopian tube, or peritoneal carcinoma at the University of
Washington, between 1998 and 2013 and had no known familial risk for ovarian cancer

52
or had not undergone any genetic testing to date. All cases provided informed consent to
participate in the University of Washington institutional gynecologic oncology tissue
bank and related genetic study and donated about 9 ml of blood for genetic analysis. Age
at diagnosis for these women ranged from 30 through 70 years of age. All cases have
been analyzed using a BROCA assay for 52 genes including CHEK1 and CHEK2.
Controls included 557 females older than age 50, with no personal history of
breast or ovarian cancer, who gave permission for their genomic DNA to be used
anonymously for research. Healthy individuals are part of the Women’s Health Initiative
and data on controls was previously published by Kanchi et al (2014). The age of the
controls was a limitation of the dataset used for this study. The data on mutations in these
controls were generated using whole exome sequencing, which expands the genes in the
BROCA panel to all genes in the human genome and is also available online (Kanchi el
al., 2014). All participants provided informed consent for genetic studies.
Laboratory Component
Data collection in the Swisher laboratory followed laboratory testing procedures
as set forth under the Clinical Laboratory Improvement Amendments of 1988 (CLIA)
regulations and followed the general CLIA quality systems requirements for non-waived
testing and the CLIA personnel requirements for tests of high complexity.
DNA Extraction
DNA from patients was obtained from blood collected at their pre-surgery
appointments. About 9 milliliters (mls) of blood was placed in an Acid Citrate Dextrose
(ACD) containing BD vacutainer blood collection tube (Becton, Dickinson and
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Company, New Jersey) by a phlebotomist or nurse. Blood tubes were then provided to
Dr. Swisher’s laboratory, free of any personal identifiable information, where the DNA
was extracted from blood.
DNA was extracted from blood or lymphoblast cell lines by desalting method
(Walsh et al., 2011; Wickramanyake et al., 2012). The blood was centrifuged down to
separate the plasma, buffy coat and Red Blood Cells (RBC). The buffy coat was then
isolated and placed in RBC lysis buffer at a 1 to 3 ratio, incubated for 30 minutes, then
centrifuged. The pellet was resuspended in cell lysis buffer and incubated with 20% SDS
and Proteinase K (Promega) at 37oC overnight. Saturated 6M NaCl was added and then
the solution centrifuged. The supernatant was collected and mixed with 3 volumes of
pure 100% ethanol at which point the DNA precipitated out of solution, was collected,
then resuspended in Tris-EDTA solution.
Sequencing
Sequencing data for cases has been obtained from samples by undergoing
BROCA, a massively parallel sequencing approach, which allows for the sequencing of
multiple genes. To prepare the DNA for BROCA, 3ug of DNA, paired-end libraries with
150 base pair inserts were prepared and hybridized to a custom pool of oligonucleotides
targeting 52 exomic regions (Walsh et al., 2011), using SureSelectXTTM (Agilent, Santa
Clara, CA) enrichment system on a Bravo liquid handling instrument (Agilent, Santa
Clara, CA). Following capture, samples were barcoded with 96 different indexed primers,
pooled 96 per lane, and sequenced on a 2500HiSeq (Illumina, San Diego, CA) (Walsh et
al., 2011). Sequence alignment and variant calling were done against the reference human
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genome (UCSC hg19) (Walsh et al., 2010). All suspected deleterious mutations were
verified by Sanger sequencing. Polymerase chain reaction (PCR) was performed using
specific PCR primers to amplify the region where the mutations were found. PCR
amplicons were sequenced bidirectionally using the Applied Biosystems BigDye
Terminator v3.1 sequencing kit (Applied Biosystems, and analyzed on an ABI 3130xl
genetic analyzer (Wickramanyake et al., 2012). Trace sequences were analyzed using
Sequencher 4.9 software. Information on validated mutations and which samples have the
mutation will be provided to me in the form of an excel database. Controls were
sequenced by whole exome sequencing as previously described (Kanchi et al., 2014).
Research Approach
Mutations
The data provided for this study was in the form of an excel spreadsheet that
contained the code for the patient, age at diagnosis, which mutation a certain patient was
found to have (CHEK1 or CHEK2, if any), the coordinates of the mutation in the genome
as well as in the coding sequence and effect in the coding region or protein, and whether
this is a frameshift, a premature truncation (e.g. a base pair change results in a stop
codon), a splice site variation or a copy number variation, or a missense. For example,
patient X, with age at diagnosis Y, may have a CHEK2.c1100delC, which is a frameshift
deletion, which in turn results in a premature stop codon and with it a loss of a functional
protein. The BROCA approach identifies many types of mutations. Specific mutation
identification was a part of this study for any mutations within the cases or controls. This
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research only included clear loss of function mutations: frameshifts, splice site variations,
premature truncations, and copy number variations.
Missenses in CHEK2 only were counted if there was clear evidence of loss of
function of the protein. This was determined via literature review and whether functional
studies had been performed to determine if that mutation results in a loss of gene
function. Several CHEK2 missense mutations have already been identified in breast
cancer (Le Calvez-Kelm et al, 2011; Roeb, Higgings, & King, 2012; Shaag et al., 2005).
Roeb et al. (2012) published a seminal paper where functional studies have been done to
identify whether known missense mutations led to loss of function. Therefore, the
missenses reported as damaging in previously published studies and the Roeb et al.
(2012) study were included as clearly damaging mutations if present. Appendix C
includes a list of CHEK2 missenses that were considered as loss of function mutations
based on the literature. CHEK1 missense mutations were not included since none have
been reported in the literature to date.
Statistical Analysis
Data for mutations in CHEK1 and CHEK2 included how many mutations there
were in this data set and which specific mutations were identified. Cancer status was set
as the dependent variable. Independent variables included CHEK1 and CHEK2 variants
and age at diagnosis.
In order to determine the strength of the association in this study, a power analysis
was performed with PS Power and Sample Size Calculations, a freely available program
on the web (Dupont & Plummer, 1998). For this study with 587 cases and 557 controls,

56
and prior research supporting a 0.5 probability of CHEK2 mutations among controls
(Cybulski et al.,2004), a true odds ratio for mutations of 0.704 or 1.420 in cases relative
to controls with probability (power) of 0.8 should be obtainable. The type I error
probability associated with an OR=1 for this hypothesis testing was 0.05 and was based
on using -squared statistic or Fisher’s exact test to evaluate this null hypothesis. This
calculation was limited to CHEK2 since previous research has already been conducted by
other researchers to estimate percentage of mutations in controls. No such research is
available for CHEK1 and so power was not predicted prior to the analysis for CHEK1. I
also performed post-hoc power analysis to determine the level of power for my analysis.
This was calculated using PS Power and Sample Size Calculations as above and also
using the website ClinCalc.com and using their Post-hoc power calculator
(http://clincalc.com/Stats/Power.aspx).
Initial analysis determined how many mutations were identified in the cohort. I
compared the proportions of prevalence of all the alleles in CHEK1 and CHEK2 in cases
versus controls. Each gene was analyzed separately. Any mutations that resulted in a
truncated protein, which may include frameshifts, copy number variations, splice
alterations and stop gains, and functionally tested missenses in CHEK2 (see Appendix C),
were counted as a damaging mutation for each gene. Then, the sum total of damaging
mutations was compared between cases and controls, for each gene independently, to
answer the research questions as to whether CHEK1 is associated with disease or whether
CHEK2 is associated with disease. Odds ratios for mutations in either CHEK1 and/or
CHEK2 were generated using two by two tables and statistical significance was
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determined between cases and controls using Fisher’s exact test. Odds ratios were
calculated at 95% confidence intervals. Overall, this analysis investigated whether there
was a correlation between variants in these genes and disease, and presents evidence as to
whether CHEK1 and/or CHEK2 can be nominated as candidate genes for ovarian cancer.
Age at Time of Diagnosis
Age at diagnosis was asked for each study participant. For the purposes of this
research, age was analyzed within cases in ten-year increments: under 40, 40-49, 50-59,
60-69, 70-79, and 80 and over. This is supported in similar studies where the age variable
was grouped using the same increments (Shaag et al., 2005; Walsh et al., 2011)
comparing non-mutation versus mutation cases. Since controls do not have an age of
diagnosis, due to their cancer free status, it is not feasible to compare their age at time of
diagnosis with cases. Therefore, for this question I determined whether any mutation
found in either of the genes under investigation correlated with age at diagnosis. Age at
diagnosis in mutation carriers versus non-mutation cases for each gene was listed in
columns and statistical significance was determined by t test.
Protection of Human Participants
Cases provided informed consent for genetic analysis to participate in the
institutional gynecologic oncology tissue bank as approved by the human subjects
division of the institutional review board of the University of Washington (University of
Washington Protocol 34173). Data from controls was from Kanchi et al., 2014
(Lic#3695490410900). No original data was collected on either cases or controls. No
personal identifiers are connected with any of the existing data I obtained from cases and
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controls. This study obtained approval and sought out protection from Walden
University’s Institutional Review Board, IRB approval #12-09-14-0059711.
Dissemination of Findings
Findings from this study will be presented at professional conferences and
submitted for publication to a peer-reviewed journal.
Summary
This study is a case-control quantitative study that aimed to determine whether
mutations in CHEK1 and CHEK2, two genes involved in promoting DNA repair, are
associated with development of ovarian cancer and whether age at diagnosis is different
for those people with mutations in these genes.
Chapter 4 presents the results for this study.
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Chapter 4: Results
Introduction
The purpose of this study was to compare the rates of mutations in CHEK1 and
CHEK2 for ovarian cancer cases to healthy controls.If mutations were identified in the
cases and/or controls, the plan was to determine whether there was an association
between mutations in these genes and ovarian cancer. The plan also sought to establish
whether age at diagnosis was lower in cases with mutations than in those without
mutations, since it has previously been shown that women with mutations have a lower
age of diagnosis than those without mutations (Boyd et al., 2000; Rish et al., 2001; Pal et
al., 2005; Alsop et al., 2012).
This chapter introduces descriptive statistics for the study population and provides
inferential statistics for each research hypothesis. It concludes with a summary and
interpretation of the data for each hypothesis.
Study Population
Cases included in this study (n = 587) were women with fallopian tube, primary
peritoneal, and/or ovarian cancer whose DNA were sequenced by Dr. Swisher’s
laboratory cases. Controls (n = 557) were healthy women with detailed sequencing
information . The total population size for this study was N = 1144.
Descriptive Statistics
Demographic information available for this cohort included sequencing
information as well as gene and chromosomal coordinates. More specifically for controls,
there was also age at time of enrollment. More detailed information was available for
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cases, which included age at diagnosis and type of cancer patient was diagnosed with,
and whether it was primary peritoneal, fallopian tube, or ovarian cancer. The following
table summarizes the age at diagnosis for all cases and type of cancer they were
diagnosed with. Table 2 shows the age of controls at time of enrollment. All are above 50
years of age and assumed to be cancer free at time of enrollment. No other demographic
information was available for this study.

Table 1
Age at Diagnosis and Cancer Site for Cases
Number of cases (%)
Age at diagnosis
<40
40-49
50-59
60-69
70-79
80 and up
No age available
Mean age
Cancer site
Fallopian tube
Primary peritoneal
Ovarian

31 (5.3)
84 (14.3)
153 (26.1)
172 (29.3)
81 (13.8)
29 (4.9)
37 (6.3)
59.45
93 (15.9)
57 (9.7)
437 (74.4)

61
Table 2
Age at Enrollment for Controls
Age at baseline Number of controls (%)
<40
40-49
50-59
60-69
70-79
80 and up
Mean age

0
0
209 (37.5)
206 (36.9)
142 (25.4)
0
63.3

Mutation Status Summary
Sequencing for mutations in a large number of genes was performed for cases and
controls, and all available information was provided for this study. The genes that were
queried and where mutations were found were ATM, ATR, BARD1, BRCA1, BRCA2,
BRIP1, CHEK1, CHEK2, FAM175A, MSH2, MSH6, NBN, PALB2, RAD50, RAD51C,
and RAD51D. Deleterious loss of function mutations were found in 141 cases, which
represented 24.02% of all cases. Deleterious loss of function mutations were found in 23
controls, which represented 4.28% of all controls. Fisher’s exact test was used to
determine the association between cases, controls, and mutations. There was statistical
significance with mutations being more strongly associated with cases than controls (p <
0.0001). The odds ratio for this association was found to be OR = 8.5 (95% CI = 5.3 to
13.8). Table 3 shows the distribution of mutations in cases and controls and in which
genes these mutations were found. Of those cases with mutations, 24 (17%) had been
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diagnosed with fallopian tube carcinoma, 103 (73%) with ovarian carcinoma, and 14
(10%) with primary peritoneal carcinoma.
Table 3
Distribution of Mutations in Cases and Controls
Genes in which mutations
Cases Controls
were identified
ATM
3
1
ATR
1
1
BARD1
1
0
BRCA1
67
6
BRCA2
32
4
BRIP1
6
1
CHEK1
2
1
CHEK2
7
2
FAM175A
1
2
MSH2
1
2
MSH6
2
2
NBN
3
0
PALB2
4
0
RAD50
1
1
RAD51C
6
0
RAD51D
4
0
Total individuals
with mutations
No mutations

141

23

446

534

p<0.0001 (Fisher’s exact test)
OR=8.5 (95%CI=5.2-13.8)

There were 2 cases and 1 control with CHEK1 mutations as well as 7 cases and 2
controls with CHEK2 mutations. The description of the CHEK1 and CHEK2 mutations
are listed in Table 4 (CHEK2 mutations) and Table 6 (CHEK1 mutations). All cases with
CHEK1 and CHEK2 mutations were diagnosed with Stage 3 ovarian cancer, rather than
primary peritoneal or fallopian tube carcinoma.
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Analysis of Hypothesis 1
All analyses were completed using Graphpad PRISM software v6.05 (San Diego,
CA). The following hypothesis was analyzed:
H1: Are CHEK2 mutated alleles associated with ovarian cancer?
H01: There are no CHEK2 mutated alleles associated with ovarian cancer.
Ha1: CHEK2 mutated alleles are associated with ovarian cancer.
The following Table 4 lists the CHEK2 case and control mutations, which is
written to describe the base pair in the cDNA coordinate that has been altered. This is
standard nomenclature for reporting mutations. Also included in the table are information
of type of mutation, effect at the protein level, and chromosomal coordinates, e.g. where
they are located in the genome. For instance CHEK2.c1100delC refers to the deletion of
base C (cytosine) at the 1100 base pair of the cDNA sequence. This mutation is located at
chromosome 22, position 29091857. The effect at the protein level is a stop at codon 381.
Finally, the type refers to whether it is a deletion, a missense, an insertion, or a nonsense.
In the case of CHEK2.c1100delC it is a deletion.
The effect at protein level for missenses (if identified as a damaging alteration) is
based on functional test and previous reports (Shaag et al., 2005; Le Calvez-Kelm et al,
2011; Roeb, Higgings, & King, 2012). For a list of damaging missense in CHEK2, see
Appendix C. All mutations result in a truncated protein that will result in a loss of
function.
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Table 4
CHEK2 Mutations in Cases and Controls

CHEK2 mutations

Genomic coordinates

Effect at protein level

Type

Cases
CHEK2.c1100delC

chr22:29091857

381 stop

deletion

CHEK2.c1100delC

chr22:29091857

381 stop

deletion

CHEK2.c1100delC

chr22:29091857

381 stop

deletion

CHEK2.c758_761delACTG chr22:29107931

252 stop

deletion

CHEK2.c428A>G

chr22:29121247

H143R,damaging
alteration

missense

CHEK2.c1283C>T

chr22:29091207

S428F, damaging
alteration

missense

CHEK2.c1283C>T

chr22:29091207

S428F, damaging
alteration

missense

Controls
CHEK2.c1229delG

chr22:29091857

367 stop

deletion

CHEK2.c499G>A

chr22:29121057

G167R, damaging
alteration

missense

For this hypothesis, CHEK2 mutation rates were first established. For the cases,
the CHEK2 mutation rate was 1.1%, whereas for controls it was 0.35%. In order to test
the hypothesis and determine an association between mutation carrier and cancer status, a
contingency table was built (Table 5) with the number of mutations in CHEK2 in cases
and controls and those participants without mutations. There were seven cases found to
have deleterious CHEK2 mutations as outlined in Table 4, and two controls with CHEK2
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mutations. This is in contrast to 446 cases and 537 controls that did not have any
mutations, either in the CHEK genes or any other genes queried by the next-generation
sequencing approach.
Table 5
Contingency Table for CHEK2 Mutations
Data analyzed
CHEK2
No mutations
Total

Cases
7
446
453

Controls
2
535
537

Total
9
981
990

The resulting odds ratio was 4.191 (95% CI = 0.87 to 20.28). The statistical
significance as calculated by a Fisher’s exact test is p = 0.0884. Based on these results, an
individual with CHEK2 mutations has a 4-fold higher likelihood of developing ovarian
cancer, but the association is weak since this analysis is not statistically significant at the
0.05 level. The confidence interval for this odds ratio crosses 1, and therefore the
association is not significant at the 0.05 level. Therefore, the alternative hypothesis is
rejected.
I performed a post-hoc power analysis and found the power to be at 30.1%, which
indicated that the alternative hypothesis was rejected 70% of the time. In this case, I
reject the alternative hypothesis.

Analysis of Hypothesis 2
The following hypothesis was analyzed:
H2: Are CHEK1 mutated alleles associated with ovarian cancer?
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H02: There are no CHEK1 mutated alleles associated with ovarian cancer.
Ha2: CHEK1 mutated alleles are associated with ovarian cancer.
The table that follows indicates CHEK1 mutations identified, their location, and
effect as explained above for Table 4. All of these mutations are loss of function
mutations that result in a truncated protein.

Table 6
CHEK1 Mutation in Cases and Controls
CHEK1 mutations
Cases

genomic coordinates

effect at protein level

type

CHEK1.c1036C>T

chr11:125,513,598

Q346 stop

stop gained

CHEK1.c1036C>T

chr11:125,513,598

Q346 stop

stop gained

chr11:125,513,598

C349fs

deletion

Controls
CHEK1.c1044_1045delAT

The rate of mutations for CHEK1 in cases was 0.34% and in controls was 0.18%.
Table 7 shows the contingency table used to calculate the odds ratio and p-value for this
analysis. CHEK1 mutations were found in 2 cases and 1 control, whereas 446 cases and
535 controls had no mutations in either CHEK1, CHEK2, or any other genes queried.
Table 7
Contingency Table for CHEK1
Data analyzed
CHEK1
No mutations
Total

Cases
2
446
448

Controls
1
534
535

Total
3
980
983
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The odds ratio for the likelihood of developing ovarian cancer if there is a CHEK1
mutation present is OR = 2.4 (95% CI = 0.22 to 26.66). The statistical significance as
calculated by a Fisher’s exact test is p = 0.59, which indicates that this association is not
significant. Moreover the confidence interval crosses 1, therefore the association is not
significant at the 0.05 level. I also performed a post-hoc power analysis for this question,
and found the power to be 7.7%. Therefore, the alternative hypothesis was rejected.
Analysis of Hypothesis 3
Literature indicates that ovarian cancer cases with mutations are diagnosed with
the disease at a younger age (Boyd et al., 2000; Rish et al, 2001; Pal et al., 2005; Alsop et
al., 2012). When comparing the mean age at diagnosis between those cases with
mutations and those without mutations, age is lower for those with mutations (54) than
those without (61) [Table 8]. This difference is statistically significant at p < 0.0001. The
following hypothesis was analyzed:
H3: Are CHEK1 mutated alleles associated with younger age (<60 years of age)
at diagnosis in ovarian cancer cases?
H03: There is no association between younger age at diagnosis and
CHEK1 mutations in ovarian cancer cases.
Ha3: Mutated alleles in CHEK1 are associated with younger age (<60
years of age) at diagnosis in ovarian cancer cases.
Table 8 shows age for all cases with mutations and without mutations. The first
column indicates age at diagnosis. There was no age at time of diagnosis available for 29
wildtype cases and 8 mutation carrier cases, indicated by NA. The second column
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indicates the number of cases with no mutations for each age group. The third column
shows number of cases with mutations in any of the genes queried for each age group.
Genes queried were: ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, CHEK2,
FAM175A, MSH2, MSH6, NBN, PALB2, RAD50, RAD51C, and RAD51D. The fourth
column shows CHEK1 mutation carriers at time of diagnosis in cases whereas the fifth
column shows CHEK2 mutation carriers at time of diagnosis. The ages at diagnosis for
those with CHEK1 mutations carriers were 42 and 43. The ages at diagnosis for CHEK2
mutations carriers were 31, 40, 45, 59, 60, and 68. There was no age at time of diagnosis
reported for one of the CHEK2 mutation carriers. The final column shows the number of
cases with either CHEK1 or CHEK2 mutations.

Table 8
Age at Time of Diagnosis for all Mutation carriers, CHEK1 only, and CHEK2 only
Mutation Carriers Versus non Carriers Among Cases

Age group at
time of
diagnosis
less than 40
40-49
50-59
60-69
70-79
80+
NA

No
mutations

Cases with a
mutation in
any of genes
queried

CHEK1
only

CHEK2
only

CHEK1
and
CHEK2
combined

21
52
106
138
72
28
29

10
32
47
34
9
1
8

0
2
0
0
0
0
0

1
2
1
2
0
0
1

1
4
1
2
0
0
1
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Table 9 shows the median age for all cases without mutations, the median age for
all cases with mutations, and the p-value comparing median age for cases with mutations
versus no mutations. It also shows the median age for CHEK1 and CHEK2 mutations
determined at diagnosis and the corresponding p-values versus cases without any
mutations. Because CHEK1 and CHEK2 genes encode for protein kinases with similar
function, I also combined the age at time of diagnosis for all CHEK1 and CHEK2
mutations carriers, see Table 8, last column, and determined the median age as well as the
p-value versus non mutation carriers, as shown on Table 9, last row.
Table 9
Average Median Age and p-Values for Age at Time of Diagnosis in Cases With and
Without Mutations
Median Age
No mutations
All mutation carriers
CHEK1
CHEK2
CHEK1 and CHEK2

61
54
42.5
50.5
48.5

p-value vs. cases with no
mutations
<0.0001
0.0398
0.0456
0.0061

In order to determine whether ovarian cancer patients with mutations in CHEK1
are diagnosed at a younger age than those with no mutations, an unpaired t test was
performed between the ages of the 2 mutation carriers and the ages of the 417 that did not
carry any mutation. A contingency table and  square analysis was not possible since
more than 20% of values were below 5 and there were many values of 0 for CHEK1
mutation carriers. The unpaired t test resulted in a p-value of p = 0.04 (p < 0.05, 95% CI
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= 0.8617-35.96), indicating that there is statistical significance between the ages of the
cases with CHEK1 mutations and those with no mutations. The mean age for cases with
CHEK1 mutations was 42.5 versus 61 for cases without mutations. Therefore, the
alternative hypothesis is accepted and the null hypothesis is rejected. I performed a posthoc power analysis for this question and obtained a power of 82.9%.

Analysis of Hypothesis 4
The following hypothesis was analyzed:
H4: Are CHEK2 mutated alleles associated with younger age (<60 years of age)
at diagnosis in ovarian cancer cases?
H04: There is no association between younger age at diagnosis and
CHEK2 mutations in ovarian cancer cases.
Ha4: Mutated alleles in CHEK2 are associated with younger age (<60
years of age) at diagnosis in ovarian cancer cases.
Table 8 shows ages for those cases with CHEK2 mutations compared to those
without mutations. Once again an unpaired t test was performed to determine statistical
significance. Table 9 shows the median age as well as the p-value obtained when
comparing the age at diagnosis of CHEK2 mutations carriers versus those cases with no
mutations. This test indicated that the difference between the two groups was statistically
significant at a 95% confidence level, with p = 0.045 (p < 0.05, 95% CI = 0.203-20.61).
The mean age for those cases with CHEK2 mutations was 50.5, while the mean age for
those without mutations was 61. Therefore, the alternative hypothesis is accepted and the
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null hypothesis is rejected. The post-hoc power calculated for this analysis was at 99%,
which allows me to reject the null hypothesis.
In addition to determining the individual significance of the mutations carrier’s
age at diagnosis for each of the CHEK genes, I sought to determine whether mutation
carriers in either of both genes combined have a lower age at time of diagnosis than those
cases without mutations. There were nine cases with either CHEK1 or CHEK2 mutations,
but for one of the CHEK2 mutations carriers there was no age at diagnosis available. The
median age for all CHEK1/2 mutation carriers was 48.5 and the p-value = 0.0061 (p <
0.05, 95% CI = 3.564-21.25) (Table 9). Combined, the association of younger age at
diagnosis and harboring a mutation is lower than in each gene individually. The post-hoc
power analysis provided a power of 100%, showing that there will not be a type II error
(known also as a false negative).
Summary
There is no clear association between CHEK1 and CHEK2 mutations and ovarian
cancer within this cohort. Yet the data supports an association between age at diagnosis
and CHEK1 and CHEK2 mutations. There is a clear association between diagnosis at a
younger age (less than 60) when harboring a mutation in CHEK1 and CHEK2 compared
to those cases without any mutations found.
Chapter 5 presents an overview and summary of the research, limitations of the
study, an interpretation of the findings, implications for social change, recommendations
for action, and suggestions for further studies.
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Chapter 5: Discussion
Research Overview
Ovarian cancer is the most deadly gynecological cancer, and it is among the top
five causes of cancer-related death in American women (Surveillance, Epidemiology and
End Results, 2012). Survival rates for ovarian cancer patients are low since most women
are diagnosed at advanced stages of the disease (Goff, Mandel, Muntz & Melancon,
2000; Weissman, Weiss, & Newlin, 2012). When detected early, though, there is an
excellent chance for survival, but current methods of detection are ineffective (Goff et al,
2000). Among the most important risk factors for ovarian cancer is family history; 25%
of all new ovarian cancer cases are due to hereditary breast and ovarian cancer from
mutations in cancer-associated genes (Pennington & Swisher, 2012). The genes that are
most often affected are genes involved in DNA repair pathways (Pennington & Swisher,
2012).
Two very important genes have been identified as contributors to ovarian cancer:
BRCA1 and BRCA2 (Check, 2006). Mutations in BRCA1 contribute to about 48% of
cases with inherited ovarian cancer, while BRCA2 accounts for about 27% (Pennington &
Swisher, 2012). Other genes in the DNA repair pathways account for about 25%
(Pennington & Swisher, 2012). Yet there are many women with inherited ovarian cancer
where no mutations are identified in the known cancer-associated genes. Therefore, other
genes in the DNA repair pathway may harbor mutations that could be responsible for the
disease .
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The purpose of this study was to determine if two genes previously not identified
as ovarian cancer-associated genes could be included this grouping. These two genes,
CHEK1 and CHEK2, which encode for proteins that function similarly, are both
mediators of the DNA damage response (Reinhardt & Yaffe, 2009; NCBI, 2014a; NCBI,
2014b). CHEK2 has previously been associated with breast cancer susceptibility
(Cybulski et al., 2004; Shaag et al., 2005; Reinhardt & Yaffe, 2009). But not much is
known about CHEK1 and its association with cancer. Previous reports found CHEK1
mutations in an ovarian cancer cohort; the authors reported the rates but did not pursue a
case control study (Pennington et al. 2013a). Thus, to date, no association study has been
undertaken for mutated CHEK1 and ovarian cancer to look at cases and controls.
This study aimed to compare the rates of mutations of CHEK1 and CHEK2 in an
ovarian cancer cohort to rates in controls. It also sought to establish whether women with
mutations in these genes were diagnosed at a younger age than cases with no mutations at
all. Many studies have reported that women with mutations in cancer-associated genes
present with disease at a younger age (Boyd et al., 2000; Risch et al., 2001; Pal et al.,
2005; Alsop et al., 2012).
In order to perform this study, sequencing data were obtained from a cohort of
1,144 women: 587 cases with ovarian cancer and 557 controls. This secondary data
analysis assessed the mutations identified by next-generation sequencing techniques in
known cancer genes, as well as the CHEK1 and CHEK2 genes of interest. The mutations
were compared in the two cohorts and contingency tables were built to ascertain the odds
ratio for association of mutation with disease. In addition, t tests were used to determine
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whether there was an association between the age at time of diagnosis and mutation status
in cancer cases. The rates of mutations in CHEK2 and CHEK1 were higher in cases than
in controls. Once the analysis was completed, Ha1 and Ha2 were rejected, indicating there
was no clear association between mutation in either CHEK1 or CHEK2 and ovarian
cancer. T tests of age at diagnosis of cases with mutations compared to those without
mutations resulted in rejecting the null hypothesis three and null hypothesis four,
resulting in an association between age at time of diagnosis in CHEK1 and CHEK2
mutations carriers than in cases with no mutations at all.
Interpretations of the Findings
I found that the overall rate of mutation in cases was higher than in controls, with
24% of cases harboring mutations in the genes queried versus only 4.3% of controls with
mutations. These results are in agreement with previous studies that have shown that
ovarian cancer cases harbor mutations in genes at a rate of 25 - 30% (Walsh et al., 2011;
Minion et al., 2015). I also found that those cases with mutations in any related gene
analyzed were younger at diagnosis than cases that were wildtype for any mutations (Pal
et al., 2012; Cunningham et al., 2014). Overall, the mutation rates and age at diagnosis
for mutation found in cases all mirror previous studies.
Regarding the CHEK1 and CHEK2 mutation rates, they were higher in cases than
controls. But despite those observations the findings of this study do not support an
association between mutations in either CHEK1 or CHEK2 and development of ovarian
cancer due to the lack of statistical significance and lack of power. It was, however, able
to support the hypothesis that women with mutations in either gene would present with a

75
diagnosis of cancer at an earlier age than women without a mutation in either of these
genes. Not only are mutations in each individual gene associated with younger age at
diagnosis in cases but both genes combined make a stronger point that mutations in those
genes are associated with diagnosis at a younger age.
The rate of CHEK2 mutation in this cohort of cases was 1.1%, which was lower
than previously reported (Pennington et al, 2013a; Minion et al., 2015). The odds ratio for
women with cancer harboring CHEK2 mutations versus controls, was OR = 4.191 with a
95% CI between 0.87 and 20.28. While the odds ratio is above 1 and would suggest a
relationship between ovarian cancer and CHEK2 mutations, the confidence interval
crosses the null value of 1 and therefore makes this result not statistically significant and
therefore I have to reject the alternative hypothesis. In addition to the confidence interval
crossing the null value, a post hoc power analysis resulted in a power of 30.1%,
suggesting that the possibility for a type II error was large and would deem this analysis
not significant. While the statistical significance is not there, it would be inappropriate to
conclude completely that there is no association and the interpretation of the OR crossing
the null value would suggest that more studies are needed (Young & Lewis, 1997). These
results, along with a low power, are most likely due to the small sample size in this
cohort and the rarity of the variants identified. A larger sample size may result in a more
statistically significant result.
CHEK2 has previously been associated with development of breast cancer,
thyroid cancer, and prostate cancer (Cybulski et al., 2004). The allele that Cybulski et al.
(2004) analyzed in those three type of cancers as well as in ovarian cancer is
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CHEK2.1100delC, and is one of the ones found within this cohort in three cases. Their
findings were also negative for an association with ovarian cancer with their odds ratio
being OR=1 for that specific allele (Cybulski et al., 2004).
A second allele found among ovarian cancer cases in this dissertation study was
CHEK2.S428F (CHEK2.c1283C>T), a variant found to increase breast cancer risk by
two-fold in women of Ashkenazi descent, Italian descent, and a high risk breast cancer
family from France (Escudie et al., 2010; Manoukian et al. 2011; Shaag et al., 2005).
This allele was the second most common one found among ovarian cancer cases in this
study. The lack of association in this study does not allow me to infer that these cases
have an increased risk for ovarian cancer but based on other studies it suggests that these
women have an increased risk for breast cancer and HBOC in addition to having suffered
from ovarian cancer.
This study could not establish a statistically significant association between
ovarian cancer and mutations in CHEK2, and the alternative hypothesis was rejected due
to the fact that the OR crosses the null value and the lack of power. In addition I found an
association between development of cancer at younger age when having mutations in this
gene and therefore, I believe that there may be some implications for cancer development
when harboring mutations in this gene. The inclusion of CHEK2 in a panel of genes for
diagnostic sequencing should not be rejected and it would still be an important asset for
ovarian cancer and breast cancer pre-screening.
CHEK1mutations showed at a rate of 0.34% in cases and 0.18% in controls. This
CHEK1 mutation rate was lower than the only other time there was an observation of a
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CHEK1 mutation in an ovarian cancer cohort (Pennington et al, 2013a). There was also
no clear association between disease and mutation. The odds ratio was OR = 2.4, with
95% CI = 0.22 to 26.66. Once again while the odds ratio is higher than 1, which would
indicate that there could be a positive association between disease and mutation in
CHEK1, the confidence interval crosses the null value which makes this OR not
statistically significant. I also performed a post-hoc power analysis for these events and
found the power to be 7.7%, which suggests a lack of power overall. This is most likely
due to the fact that the mutations were rare variants in a relatively small cohort.
Previous research on association with CHEK1 and cancer is limited. A study by
Lin et al. (2013) addressed the association between common alleles in CHEK1 and breast
cancer and found no association. A group of Finnish researchers who looked at genomic
rearrangements did not find any large insertions or deletions in CHEK1 in breast cancer
patients (Solyom, Pylkas, & Winqvist, 2010). However, their sample size was also small
and these large genomic rearrangements are also very rare events (Solyom, Pylkas, &
Winqvist, 2010). It seems therefore that this dissertation research only adds more
questions as to whether CHEK1 could be a gene associated with ovarian cancer. The
results were not statistically significant, so further studies with a larger cohort may be
needed to clarify an association. Further research into the association of CHEK1 mutation
and ovarian cancer may shed more light on how protein CHEK1 inhibitors can be used
for treatment (Kim, Min, Wright, Goldlust & Annunziata, 2014; Kim, James &
Annunziata, 2015). This study failed to make an association and therefore did not provide
any more insight into that aspect of CHEK1 physiology.
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While this study rejects the alternative hypothesis due to the low power and that
the OR’s 95% CI spans the null value, I cannot say (based on Young and Lewis (1997))
that it provides a lack of evidence of association between mutations in these genes and
disease. I see a decrease in the p-value when comparing ages in cases, which indicates
that these mutations most likely have an effect on disease development. When there is an
association between mutation and disease where the confidence interval is wide and not
very precise, this is due to the small sample size (Young & Lewis, 1997). The same is
true for the almost non-existent power in this analysis, that it is a result of a small sample
size and the rarity of the variants. A larger sample size would narrow the point estimate,
increase power, and clarify the results. Overall, this result indicates that the sample size is
too small, yet does not rule out an association (Young & Lewis, 1997). This
interpretation is supported when I compared my findings for CHEK1 with a population
database readily available on the internet. This publicly available database, the ExAC
browser, offered by the Broad Institute reports on variants found in 60,706 unrelated
individuals sequenced in population genetic studies (Exome Aggregation Consortium
(ExAC), 2015). When I searched for variants in CHEK1, they reported only 44 found
among 60,706. When I proceeded to calculate the odds ratio comparing my data to the
ExAC data, I obtained an odds ratio of 4.7, with a 95% CI of 1.14-19.5. Just looking at
the mutation found among the cases in this study, CHEK1.Q346X, the ExAC browser
only reports 2 individuals having that variant. This comparison resulted in an odds ratio
of 103.8 and a 95% CI of 14.59-738.3. My interpretation is that I cannot rule out an

79
association between CHEK1 and ovarian cancer and that a larger study is needed due to
the complexities of analyzing the association of disease with rare variants and mutations.
Lee, Abecasis, Boehnke & Lin, (2014), highlighted the issues that rare gene
variant association studies face statistically. According to Lee et al. (2014), single variant
testing to identify associations with low frequency and rare variants are difficult if
samples sizes are not large enough, because the power is not quite there. This was
evidenced in this study. Sample size was not high enough to provide enough power for
such rare events (Walsh et al., 2011; Pennington et al., 2013a; Minion et al., 2015).
This study also found that if cases have a mutation in either CHEK1 or CHEK2,
the likelihood of the cancer occurring earlier is higher than in cases without any
mutations. The difference in age at diagnosis between the cases harboring mutations in
either gene or both genes combined is statistically significant. The average age at time of
diagnosis of cases with CHEK2 mutations from this study is about 10 years younger than
those with no mutation. Cases with mutations are usually under age 60 (Risch et al.,
2001). The average age at time of diagnosis of cases with CHEK1 mutation was 42.5 in
this study and was also much younger than the average for the cases without mutations,
which was 61 in this study. For all instances of CHEK1 and CHEK2 mutation combined,
the median age at time of diagnosis was 48.5 years versus 61 for those cases without
mutations, as shown on Table 9, last row (p.69). This was statistically significant and
post-hoc power analysis confirmed that the power was sufficient to avoid a type II error.
These results are in line with previously reported studies where women with mutations
are usually diagnosed with disease at younger ages than cases without mutations (Risch
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et al., 2001; Pal et al., 2005; Alsop et al., 2012). In addition, when looking at all the cases
with mutations in this cohort, the median age for diagnosis for women with any
mutations in any of the genes was 54, statistically significantly younger ( p<0.0001) than
those with no mutations. These results suggest that for ovarian cancer patients harboring
mutations in any of the genes tested, including CHEK1 and CHEK2, the age that the
disease will develop is lower than in those patients without any inherited mutations
identified. This suggests testing people for inherited mutations in genes such as CHEK1
and CHEK2 as well as BRCA1 and BRCA2, may allow them to find out that these
alterations may predispose them to developing cancer at a younger age than people
without these mutations.
In summary, the study failed to establish a clear association between mutations in
the genes CHEK1 and CHEK2 most likely due to the small cohort investigated and the
rarity of the variants. Yet the age of diagnosis of cases with mutations in either of these
genes was found to be statistically significantly younger for those with mutations
compared to those without mutations. These results taken together do not rule out a
possible role for CHEK1 and CHEK2 in ovarian cancer.
Limitations of the Study
During the analysis of the secondary data available it became obvious that
this study had a very big limitation. Given the rarity of the variants analyzed, the size of
the cohort was too small to establish any significant association regarding the existence
of mutations in CHEK1 and CHEK2 and ovarian cancer. While the overall rates of
mutations were comparable to other studies published, the rates for CHEK1 and CHEK2
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were lower than previously reported. Gene sequence analysis may have missed mutations
due to incorrect reporting or using the wrong variant of the gene nomenclature. Also
there may have been mutations that could have been reported as germline mutations but
they could have been somatic mutations of tumor circulating in the blood. If the
percentage of the variant reads are low, many times it is due to circulating tumor in the
blood and the sequencing will pick it up in the germline DNA. If this is not identified
accurately, a somatic mutation could be interpreted as a germline mutation, and with it
provide a false information. It is assumed that there was accurate reporting of the
sequencing information, but this could not be verified personally as I did not have access
to that more specific information and was beyond the scope of this study.
In addition, there was limited data available for the cohort in general, and this
limited the analysis to sequencing data, cancer site, and age. Additional information on
other cancers was not available either, which would have been helpful to evaluate
whether some of these women have had breast cancer prior to their ovarian cancer. Some
of these mutations have been found to be present in breast cancer patients in other studies
and so it could have informed me of whether this cancer was a recurrence of cancer at
another site or a primary event.
It would have been helpful to have familial information on these cancer cases to
determine whether these ovarian cancers were inherited or sporadic. Having segregation
data on the family as well as family history could have informed me more thoroughly of
the effect of these mutations on cancer development.
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This sample set represented a relatively small cohort that was enrolled within this
region of the Pacific Northwest. I am unsure of how the makeup of this cohort represents
the diversity of the U.S. and how these mutations were at all related to ethnicity. We
know that in breast cancer certain CHEK2 mutations are prevalent in women of
Ashkenazy Jewish descent or Czechoslovakian descent (Cybulski et al, 2004; Shaag et al,
2005), and so not knowing this aspect of the patients could not allow for an association
based on ethnicity or race.
One of the bigger limitations of this study that came to light in the analysis stage
was cohort size. While a priori power analysis indicated that the size would be sufficient,
the rate of mutations found and the rarity of the alleles resulted in an underpowered study
that could not establish a clear association between disease and variants. This could be
remedied by proceeding with larger studies.
Recommendations
As an approach to improve this study and to obtain statistically significant values,
there is a need to obtain a larger number of cases and many more controls known to be
cancer free. As Lee et al., (2014) state, rare variants can be found to have associations
with disease if the effect and the sample size is large. They also suggest that research in
rare variant analysis may have to evolve from current methods and “will require more
methodological development” (Lee, Abecasis, Boehnke, & Lin, 2014, p. 9). In order to
have larger sample sizes and more of a representative sample of the U.S. population,
several institutions should join together into a multi-center study that will allow testing of
many individuals that have ovarian cancer. In addition, the number of controls should be
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higher than that of the cases in order to be able to reach strong predictive values for odds
ratios (Young & Lewis, 1997). Organizations like the Gynecologic Oncology Group
(GOG), the Ovarian Cancer Association Consortium (OCAC), and the Australian
Ovarian Cancer Study (AOCS), are beginning to undertake such studies that will
sequence a large number of probands and will help answer the question as to whether
some candidate genes such as CHEK1 and CHEK2 can be upgraded to cancer-associated
genes.
In the meantime, women should continue to enroll in genetic testing studies such
as the one that these data were obtained from. Ovarian cancer patients and their families
should continue to be tested on next-generation sequencing panels, which contain many
cancer-associated genes as well as candidate genes such as CHEK1 and CHEK2. This
study failed to show a positive association between ovarian cancer and CHEK1 and
CHEK2 due to the lack of power and the 95% CI crossing the null value, despite the odds
ratio being above 1. This leads to no definite conclusions, but being that the odds ratios
obtained are above 1 and the fact that there was an association between mutations in
these genes and younger age at time of diagnosis, the results suggest the possibility that
these genes may be associated with ovarian cancer. Continued testing will increase the
number of individuals tested for mutations in those genes and the accumulation of results
from the sequencing studies will add to the knowledge regarding these genes and others.
In addition, in order to have a better understanding as to whether these genes can
be upgraded to ovarian cancer associated genes, I need to determine the segregation
among affected families. Establishing whether this mutation is inherited in cancer cases

84
within a family is a hallmark of establishing whether a gene can be associated with the
cancer in that family (Newman, Millikan, & King, 1997). This information was not
available for this study and was beyond the scope of the IRB approval, but another study
which provides information on familial segregation and pedigrees could be undertaken.
Further information on the cases could also provide insight into their risk for
breast cancer. Several of the alleles in CHEK2 had previously been associated with breast
cancer by Cybulski (2004) and others (Mellemkjaer et al., 2008; Weischer, Bojesen,
Ellervik, Tybjaerg-Hansen, & Nordestgaard, 2008). Research on whether these ovarian
cancer patients have a history of breast cancer or have taken precautionary methods to
prevent breast cancer or are under surveillance for developing breast cancer is needed.
Additional information can also be gleaned from functional studies to determine
how mutations in these genes affect the proper functioning of the protein. If functionality
of the protein is affected, this can be established experimentally in cells and other model
systems, such as yeast, mammalian cells, and mice. Segregation in families, functional
studies, and larger case control studies will help me determine whether candidate genes
can be considered cancer associated genes.
Implications for Social Change
Recognizing potential causes for ovarian cancer is an important tool for early
detection. Ovarian cancer is many times referred to as the silent killer, because many
patients go undiagnosed until late in the stage of disease when treatment is often too late
and survival is marginal (Goff et al, 2000). Since inherited ovarian cancer is responsible
for about 25% of cases, a better knowledge of genes associated with a diagnosis would
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help in identifying potential cases. Genetic testing is becoming more available and
affordable for the general public. This is a helpful tool to pre-screen for potential ovarian
cancer or allow for early detection. Currently researchers and many doctors know that
BRCA1, BRCA2, PALB2, BRIP1, RAD51C, and RAD51D are genes that contribute to
cases of inherited ovarian cancer (Pennington & Swisher, 2012). All of these genes are in
the DNA repair pathway. But there are other inherited ovarian cancer cases where these
genes are not mutated. Other mutated genes in this pathway may, instead, be contributing
to the cancer development. Therefore research identifying these genes could provide
information for family members with a strong history of familial cancers.
This knowledge would allow women to undergo increased surveillance and
prophylactic efforts to prevent cancer. Most recently a paper by Easton et al. (2015),
called out for the need of well-designed population- and family-based studies in
populations that are highly diverse so that practitioners can provide accurate counseling
of disease risks. Not only will it help patients understand their risk but will also help to
inform researchers with this broad and systematic collection of data that would link
clinical and epidemiological data to outcomes and risk (Easton et al., 2015). Access to
such data and new level of understanding not only contributes to a positive outcome for
ovarian and breast cancer patients or those at risk but also for people facing other
complex inherited diseases as prostate cancer, colon cancer, etc.
Doctors who are dealing with patients with a family history of ovarian cancer
need to be aware of the hereditary aspect of this disease. It is important they also
understand that testing is important and to approach their patients about genetic testing so
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that they can work on a prophylactic plan not only for the patients but also for the rest of
the family, especially if the patient has children (American Cancer Society, 2015).
Insurance companies are coming around to paying for these services when the
family history warrants a test (American Cancer Society, 2015). It is in their own interest
to invest in knowledge and prophylaxis rather than having to pay for treatment. The cost
of treatment for the disease is much larger than that for prophylactic approaches and risk
reducing surgery than for prolonged therapy and treatments (Grann, Panageas, Whang,
Antman, & Neugut, 1998).
The more genes researchers and doctors as well as patients are aware of with a
role in ovarian cancer development, the more information all have in the arsenal against
ovarian cancer. While this study did not establish a clear association between CHEK1 and
CHEK2 mutations with ovarian cancer, it showed that women with mutations in these
genes are diagnosed at younger age. Knowing this provides information that will help
people take action earlier. Patients with known mutations can then develop a plan with
their physician to undergo half yearly exams with transvaginal ultrasounds and CA-125
testing that will hopefully help with early detection (ACOG, 2002). Following this the
plan can be expanded to include risk reducing surgery when the patient is ready (ACOG,
2002). These approaches that are based on knowing your family history and mutational
status can lead to reduced mortality rates.
Conclusion
The aim of this study was to determine whether mutations in CHEK1 and
CHEK2, two genes within the DNA repair pathway, were associated with ovarian cancer
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and whether mutations in these genes were associated with a younger age at diagnosis.
While the odds ratios for association between ovarian cancer and mutations in both genes
were above the null value of 1, the 95% confidence interval crossed the null value in both
cases indicating a lack of statistical significance. This statistical outcome resulted in the
alternative hypothesis being rejected. Results suggest that the sample size was too small
to establish a clear association for such rare events. This, paired with the statistical
significance for younger age at diagnosis in cases with mutations in CHEK1 and CHEK2
makes a strong point against completely dismissing a lack of association between
mutations in these genes and ovarian cancer.
Larger studies with more cases and more controls and cooperation between
multiple centers would be needed to further study these potential genes as candidate
genes. Also, studies that include segregation in cancer families as well as functional
studies into the effect of these mutations on the protein function would support
conclusions gleaned from case-control studies. What is certain is that with the advent of
next-Generation sequencing, the lower cost and the increasing availability of panel
testing will allow patients to get diagnostic testing that may help with earlier detection or
preventative measures. Such testing supports social change by allowing patients to take
an active role in prevention, including prophylaxis and surveillance, and reducing
mortality from ovarian cancer due to delayed detection.
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Appendix A: Syndromes of Inherited Cancer Predisposition

Syndrome (OMIM
entry)
Hereditary breast cancer
syndromes
Hereditary breast cancer
and ovarian cancer
syndrome (113705,
600185)

Li-Fraumeni Syndrome
(151623)

Cowden Syndrome
(158350)

Bannayan-RileyRuvalcaba syndrome
(153480)

Ataxia telangiectasia
(208900)

Component Tumors

Mode of
Inheritance

Genes

Breast cancer
Ovarian cancer
Prostate cancer
Pancreatic cancer
Fanconi
anemia/medulloblastoma
Soft tissue sarcoma

Dominant

BRCA1
BRCA2

Recessive

BRCA2

Dominant

p53

Breast cancer
Osteosarcoma
Leukemia
Brain tumors
Adrenocortical carcinoma
Breast cancer

CHEK2

Dominant

PTEN

Thyroid cancer
Endometrial and other
cancers
Breast cancer

Dominant

PTEN

Meningioma
Thyroid follicular cell
tumors
Leukemia

Recessive

ATM

Dominant

MLH1
MSH2
MSH6

Lymphoma
Hereditary
gastrointestinal
malignancies
HNPCC, including
“Lynch II” syndrome
(120435, 120436,
114500, 114400)

Colon cancer
Endometrial cancer
Ovarian cancer
Renal pelvis cancers
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Ureteral cancers
Pancreatic cancer
Stomach and small bowel
cancers
Hepatobiliary cancers
Familial polyposis,
including attenuated
phenotype (175100)
Familial attenuated
polyposis (175100)
Hereditary gastric
cancer (137215)
Juvenile polyposis
(174900)

Dominant

APC

Colon cancer

Dominant

APC

Stomach cancers

Dominant

CDH1

Gastrointestinal cancers

Dominant

SMAD4/DPC4

Dominant

BMPR1A
STK11

Dominant

CDKN2A/p16

Dominant

PRSS1

Dominant

APC

Pancreatic cancer
Peutz-Jeghers syndrome Colon cancer
(175200)
Small bowel cancer
Breast cancer
Ovarian cancer
Pancreatic cancer
Hereditary melanoma
Pancreatic cancer
pancreatic cancer
Melanoma
syndrome (606719)
Hereditary pancreatitis
Pancreatic cancer
(167800)
Turcot Syndrome
Colon cancer
(276300)
Basal cell carcinoma
Ependymoma
Medulloblastoma
Glioblastoma
Familial gastrointestinal Gastrointestinal stromal
stromal tumor (606764) tumors
Genodermatoses with
cancer predisposition
Melanoma syndromes
Malignant melanoma
(155600, 155601,
609048, 608035)
Basal cell cancers,
Basal cell cancers
Gorlin syndrome
(109400)

MLH1
PMS2

Dominant

KIT

Dominant

CDKN2 (p16)
CDK4
CMM
PTCH

Dominant
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Cowden Syndrome
Neurofibromatosis 1
(162200)

Neurofibromatosis 2
(101000)
Tuberous sclerosis
(191100)

Carney Complex
(160980, 605244)

Muir Torre syndrome
(158320)

Xeroderma
pigmentosum (278730,
278700, 278720,

Brain tumors
See above
Neurofibrosarcomas

Dominant
Dominant

PTEN
NF1

Pheochromocytomas
Optic gliomas
Meningiomas
Vestibular schwannomas

Dominant

NF2

Dominant

TSC1

Myocardial
rhabdomyoma
Multiple bilateral renal
angiomyolipoma
Ependymoma
Renal cancer
Giant cell astrocytoma
Myxoid subcutaneous
tumors
Primary adrenocortical
nodular hyperplasia
Testicular Sertoli cell
tumor
Atrial myxoma
Pituitary adenoma
Mammary fibroadenoma
Thyroid carcinoma
Schwannoma
Sebaceous carcinoma
Sebaceous epitheliomas
Sebaceous adenomas
Keratoacanthomas
Colon cancer
Laryngeal carcinoma
Malignant gastrointestinal
tract tumors
Malignant genitourinary
tract tumors
Skin cancer
Melanoma
Leukemia

TSC2

Dominant

PRKAR1A

Dominant

MLH1
MSH2

Recessive

XPA,B,C,D,E,F,G
POLH
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278760, 74740, 278780,
278750, 133510)
Rothmund Thomson
Basal cell carcinoma
syndrome (268400)
Squamous cell carcinoma
Osteogenic sarcoma
Leukemia/lymphoma
predisposition
syndromes
Bloom syndrome
Leukemia
(210900)
Carcinoma of the tongue
Squamous cancers
Wilms' tumor
Colon cancer
Fanconi anemia
Leukemia
(227650)
Squamous cancers
Skin carcinoma
Hepatoma
Shwachman-Diamond
Myelodysplasia
syndrome (260400)
Acute myelogenous
leukemia
Nijmegen breakage
Lymphoma
syndrome (251260)
Glioma
Medulloblastoma
Rhabdomyosarcoma
Canale-Smith syndrome Lymphoma
(601859)

Recessive

RECQL4

Recessive

BLM

Recessive

FANCA,B,C

Recessive

FANCA,D2
FANCE,F,G
FANCL
SBDS

Recessive

NBS1

Dominant

FAS
FASL

Immunodeficiency
syndromes
Wiskott-Aldrich
(301000)
Common variable
immune deficiency
(240500)
Severe combined
immune deficiency
(102700, 300400,

Hematopoietic
malignancies
Lymphomas

X-linked
recessive
Recessive
Dominant

WAS

B-cell lymphoma

X-linked
recessive
Recessive

IL2RG

Unknown
Unknown

ADA
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312863, 601457,
600802, 602450)

X-linked
lymphoproliferative
syndrome (308240)
Genitourinary cancer
predisposition
syndromes
Hereditary prostate
cancer (176807,
601518)

Simpson-GolabiBehmel syndrome
(312870)
von Hippel-Lindau
syndrome (193300)

Beckwith-Wiedemann
syndrome (130650)

Wilms' tumor syndrome
(194070)
WAGR: Wilms' tumor,
aniridia, genitourinary
abnormalities, mental
retardation (194072)
Birt-Hogg-Dubé
syndrome (135150)

Lymphoma

X-linked
recessive

Prostate cancer

Dominant

Embryonal tumors

Wilms' tumor
Hemangioblastomas of
retina and central nervous
system
Renal cell cancer
Pheochromocytomas
Wilms' tumor
Hepatoblastoma
Adrenal carcinoma
Gonadoblastoma
Wilms' tumor

X-linked
recessive

JAK3
RAG1
RAG2
IL7R
CD45
Artemis
SH2D1A

HPC1

HPCX
HPC2/ELAC2
PCAP
PCBC
PRCA
GPC3

Dominant

VHL

Dominant

CDKN1C
NSD1

Dominant

WT1

Wilms' tumor
Gonadoblastoma

Dominant

WT1

Renal tumors

Dominant

FLCL
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Papillary renal cancer
syndrome (605074)
Constitutional t(3;8)
translocation (603046)
Hereditary bladder
cancer (109800)
Hereditary testicular
cancer (273300)

Rhabdoid predisposition
syndrome (601607)
Central nervous
system/vascular cancer
predisposition
syndromes
Hereditary
paraganglioma (185470,
115310, 16800)
Retinoblastoma
(180200)

Papillary renal cancer

Dominant

MET, PRCC

Renal cell cancer

Dominant

TRC8

Bladder cancer

Sporadic

Unknown

Testicular cancer

Rhabdoid tumors (see
below)

Carney complex
Werner syndrome
(277700)

Unknown
Unknown
SNF5/INI1

Paraganglioma
Pheochromocytoma

Dominant

Retinoblastoma

Dominant

SDHD
SDHC
SDHB
RB1

Dominant

SNF5/INI1

Dominant

EXT1

Dominant

EXT2
FH

Dominant
Recessive

PRKAR1A
WRN

Osteosarcoma
Rhabdoid predisposition Rhabdoid tumors
syndrome (601607)
Medulloblastoma
Choroid plexus tumors
Primitive
neuroectodermal tumors
Sarcoma/bone cancer
predisposition
syndromes
Multiple exostoses
Chondrosarcoma
(133700, 133701)
Leiomyoma/renal
cancer syndrome
(605839)

Unknown
Possibly xlinked
Possibly
recessive
Dominant

Papillary renal cell
carcinoma
Uterine leiomyosarcomas
See above
Sarcoma/osteosarcoma
Meningioma
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Endocrine cancer
predisposition
syndromes
MEN1 (131100)

MEN2 (171400)

Pancreatic islet cell
Dominant
tumors
Pituitary adenomas
Parathyroid adenomas
Medullary thyroid cancers Dominant
Pheochromocytoma
Parathyroid hyperplasia
Papillary thyroid cancer
Dominant

MEN1

RET

Familial papillary
Multiple loci
thyroid cancer (188500)
Syndromes of Inherited Cancer Predisposition in Clinical Oncology Syndrome.
From“Hereditary Cancer Predisposition Syndromes”, by J. Garber and K. Offit, 2005,
Journal of Clinical Oncology, 23(2), p. 278. Copyright 2005 by American Society of
Clinical Oncology. Adapted with permission of the American Society of Clinical
Oncology, license number 3673710531158.
Abbreviations: OMIM, On-Line Mendelian Inheritance in Man; HNPCC, hereditary
nonpolyposis colorectal cancer; MEN, multiple endocrine neoplasia.
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Appendix B: The FA-BRCA DNA Damage Response

Figure B. Schematic of some of the FA genes and other interacting proteins in the
DNA damage response. (Adapted from Harrell et al. (2013)). Germline loss of
function mutations in DNA repair genes in 1418 patients with ovarian, peritoneal or
fallopian tube cancers not selected for age at diagnosis or family history. In M.
Southey (Chair), Hereditary Cancer Syndromes. Platform session conducted at the
Annual meeting of the American Society for Human Genetics, Boston, MA.)
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Appendix C: CHEK2 damaging missenses resulting in loss of function as reported by the
literature

Chr

Position (hg19)

NT

cDNAa

Proteina

Prediction

22

29,121,326

C>T

c.349A>G

R117G

Damaging

22

29,121,247

T>C

c.428A>G

H143R

Damaging

22

29,121,242

G>A

c.433C>T

R145W

Damaging

22

29,121,077

T>C

c.480A>G

I160M

Damaging

22

29,121,058

C>T

c.499G>A

G167R

Damaging

22

29,121,019

G>A

c.538C>T

R180C

Damaging

22

29,095,917

C>G

c.917G>C

G306A

Tolerated

22

29,092,914

G>A

c.1070C>T

S357F

Damaging

22

29,091,220

A>G

c.1270T>C

Y424H

Damaging

22

29,091,207

G>A

c.1283C>T

S428F

Damaging

22

29,090,054

G>T

c.1427C>A

T476K

Damaging

22

29,090,054

G>A

c.1427C>T

T476M

Damaging

